var title_f34_28_35264="Hydrocortisone: Pediatric drug information";
var content_f34_28_35264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocortisone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12645305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/46/22249?source=see_link\">",
"       Hydrocortisone (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/33/7702?source=see_link\">",
"       Hydrocortisone (topical): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13361 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-AB557005D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35264=[""].join("\n");
var outline_f34_28_35264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/46/22249?source=related_link\">",
"      Hydrocortisone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/33/7702?source=related_link\">",
"      Hydrocortisone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35265="CT of a thymic carcinoid";
var content_f34_28_35265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F75493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F75493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Radiographic appearance of a thymic carcinoid tumor on computed tomography (CT) scanning",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial contrast-enhanced CT image of the chest showing a homogeneously enhancing anterior mediastinal mass encasing the great vessels and extending to the anterior chest wall, consistent witha &nbsp;pathologically proven thymic carcinoid tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Elsayes KM, Menias CO, Bowerson M, et al. Imaging of carcinoid tumors: Spectrum of findings with pathologic and clinical correlations. J Comput Assist Tomogr 2011; 35:72. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35265=[""].join("\n");
var outline_f34_28_35265=null;
var title_f34_28_35266="Patient information: Hypertrophic cardiomyopathy in adults (The Basics)";
var content_f34_28_35266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15753\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/46/14053\">",
"         Heart with hypertrophic cardiomyopathy",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/13/21714\">",
"         Patient information: Dilated cardiomyopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/51/25395\">",
"         Patient information: ECG and stress test (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/60/38850\">",
"         Patient information: Implantable cardioverter-defibrillators (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?43/17/44305\">",
"         Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hypertrophic-cardiomyopathy-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1731662548\">",
"      <span class=\"h1\">",
"       What is hypertrophic cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Hypertrophic cardiomyopathy is a condition that causes the muscle in the heart to get too bulky (",
"      <a class=\"graphic graphic_figure graphicRef50899 \" href=\"mobipreview.htm?13/46/14053\">",
"       figure 1",
"      </a>",
"      ). When this happens, the heart can have trouble pumping blood as well as it should. This can lead to symptoms, such as trouble breathing, chest pain, and fainting. Hypertrophic cardiomyopathy is usually caused by a genetic problem that runs in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662555\">",
"      <span class=\"h1\">",
"       What are the symptoms of hypertrophic cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with hypertrophic cardiomyopathy have no symptoms. When symptoms do occur, they can start during childhood, the teenage years, or adulthood.",
"     </p>",
"     <p>",
"      Symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble breathing, especially during exercise",
"       </li>",
"       <li>",
"        Trouble breathing that gets worse when you lie down and gets better if you sit up or stand",
"       </li>",
"       <li>",
"        Chest pain, which sometimes gets worse with activity",
"       </li>",
"       <li>",
"        Fainting or feeling like you might faint",
"       </li>",
"       <li>",
"        Feeling as though your heart is beating very fast or skipping beats",
"       </li>",
"       <li>",
"        Swelling in the feet, ankles, or legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662562\">",
"      <span class=\"h1\">",
"       Is there a test for cardiomyopathy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have cardiomyopathy, he or she will probably order an &ldquo;electrocardiogram&rdquo; (also called an &ldquo;ECG&rdquo; or &ldquo;EKG&rdquo;). This test measures the electrical activity in your heart. It can show if your heart beats in a normal pattern and rhythm.",
"     </p>",
"     <p>",
"      Your doctor may also order an &ldquo;echocardiogram&rdquo; (or &ldquo;echo,&rdquo; for short). An echo uses sound waves to create an image of the heart. This test allows doctors to measure the thickness of the walls of the heart, measure the size of the spaces inside the heart &mdash; called chambers &mdash; and see how the heart pumps. Depending on your situation, you might also need other tests.",
"     </p>",
"     <p>",
"      Since hypertrophic cardiomyopathy runs in families, your doctor or nurse might suggest testing your family members for the disorder.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662569\">",
"      <span class=\"h1\">",
"       What problems can hypertrophic cardiomyopathy cause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In many cases the condition causes no problems. But in some cases it can lead to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Heart failure, a condition in which the heart does not pump as well as it should",
"       </li>",
"       <li>",
"        Heart rhythm disorders",
"       </li>",
"       <li>",
"        Heart block, a problem that keeps electrical signals from moving through the heart as they should",
"       </li>",
"       <li>",
"        Stroke",
"       </li>",
"       <li>",
"        Infection of a heart valve",
"       </li>",
"       <li>",
"        Death",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662576\">",
"      <span class=\"h1\">",
"       How is hypertrophic cardiomyopathy treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with hypertrophic cardiomyopathy do not need treatment. Those who do need treatment can get different kinds depending on what symptoms they have and how severe their condition is.",
"     </p>",
"     <p>",
"      Treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines to relieve chest pain or trouble breathing",
"       </li>",
"       <li>",
"        Medicines to control the heart&rsquo;s rhythm",
"       </li>",
"       <li>",
"        Surgery to implant a device called an &ldquo;implantable cardioverter-defibrillator,&rdquo; or &ldquo;ICD.&rdquo; (This device keeps the heart beating normally.)",
"       </li>",
"       <li>",
"        Surgery or other treatments to remove parts of the heart muscle. (This is done only when medicines do not work.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662583\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Speak to your doctor before you start trying to get pregnant. Most women with hypertrophic cardiomyopathy are able to have normal pregnancies. But some need to change their medicines before they start trying to have a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662590\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to protect my heart and my health?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should be careful to always drink enough water. People with hypertrophic cardiomyopathy sometimes have problems, such as fainting, when they do not get enough fluids. On the other hand, some people with hypertrophic cardiomyopathy have to be careful if they have too much salt and water. Ask your doctor about how much salt is OK to have in your diet.",
"     </p>",
"     <p>",
"      It&rsquo;s also important that you ask your doctor what types of physical activity are safe for you. In many cases, people with hypertrophic cardiomyopathy need to avoid some kinds of activity.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1731662597\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/13/21714?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=see_link\">",
"       Patient information: Implantable cardioverter-defibrillators (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=see_link\">",
"       Patient information: ECG and stress test (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/28/35266?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15753 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-6C4A3AC97D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35266=[""].join("\n");
var outline_f34_28_35266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662548\">",
"      What is hypertrophic cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662555\">",
"      What are the symptoms of hypertrophic cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662562\">",
"      Is there a test for cardiomyopathy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662569\">",
"      What problems can hypertrophic cardiomyopathy cause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662576\">",
"      How is hypertrophic cardiomyopathy treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662583\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662590\">",
"      Is there anything I can do on my own to protect my heart and my health?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1731662597\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15753\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/46/14053\">",
"      Heart with hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/51/25395?source=related_link\">",
"      Patient information: ECG and stress test (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35267="Podofilox: Patient drug information";
var content_f34_28_35267=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Podofilox: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/34/23074?source=see_link\">",
"     see \"Podofilox: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Condylox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Condyline&trade;;",
"     </li>",
"     <li>",
"      Wartec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of warts.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to podofilox or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696813",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not have sex when this drug is on your genital or anal skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694533",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid putting on healthy skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11997 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-62FEFCC119-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35267=[""].join("\n");
var outline_f34_28_35267=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210945\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013000\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012999\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013004\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013005\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013007\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013002\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013003\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013008\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013009\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/34/23074?source=related_link\">",
"      Podofilox: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35268="Cyproheptadine: Patient drug information";
var content_f34_28_35268=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyproheptadine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=see_link\">",
"     see \"Cyproheptadine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/2/40996?source=see_link\">",
"     see \"Cyproheptadine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Euro-Cyproheptadine;",
"     </li>",
"     <li>",
"      PMS-Cyproheptadine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give this drug to a newborn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyproheptadine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705188",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, enlarged prostate, glaucoma, bowel block, or trouble passing urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12349 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35268=[""].join("\n");
var outline_f34_28_35268=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959840\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017088\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017087\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017092\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017093\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017095\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017090\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017091\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017096\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017097\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/25/19862?source=related_link\">",
"      Cyproheptadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/2/40996?source=related_link\">",
"      Cyproheptadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35269="Paracoccidioidomycosis distribution map";
var content_f34_28_35269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54273&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Distribution of paracoccidioidomycosis by incidence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 532px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Geographic distribution of paracoccidioidomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Colombo AL, Queiroz-Telles F. Paracoccidioidomycosis. In: Atlas of Fungal Infections, 2nd ed, Kauffman CA (Ed), Springer, Philadelphia 2007; with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35269=[""].join("\n");
var outline_f34_28_35269=null;
var title_f34_28_35270="Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients";
var content_f34_28_35270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     John W Baddley, MD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35270/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/28/35270/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20321599\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillosis refers to the illness caused by a species of the fungus, Aspergillus. A broad range of manifestations can be seen in aspergillus infection, including allergic disease, semi-invasive, and invasive disease. Although Aspergillus species are ubiquitous in nature, infection is uncommon, except in immunocompromised or immunosuppressed hosts. Patients with acquired immunodeficiency syndrome (AIDS) are susceptible to Aspergillus infection, which can lead to disseminated disease with high rates of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review the epidemiology, pathogenesis and clinical manifestations of invasive aspergillosis in patients with AIDS. The diagnosis and treatment of aspergillosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11178?source=see_link\">",
"     \"Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321606\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the years prior to the introduction of potent antiretroviral therapy (ART), invasive aspergillosis was an important cause of morbidity and mortality in patients with AIDS. In the present day, this infection is now rarely seen except among untreated patients with advanced immunosuppression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2840585\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive aspergillosis (IA) is an uncommon, although life-threatening, infection in patients with AIDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/2\">",
"     2",
"    </a>",
"    ]. Surveys from the United States demonstrate that since the introduction of potent antiretroviral therapy (ART) in 1996, the incidence of aspergillosis is low:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 35,252 HIV-infected patients in a national database, the incidence of aspergillosis was 3.5 cases per 1000 person-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      From another database of 38 million hospital discharge diagnoses nationwide, aspergillosis was diagnosed in 0.43 percent of HIV-infected patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In France, an epidemiologic survey among 3immunocompromised hosts found that the incidence of invasive aspergillosis was 0.02 to 0.13 percent per annum among HIV-infected patients, while rates were much higher among transplant recipients and patients with hematological disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/5\">",
"       5",
"      </a>",
"      ]. The disparities in rates are probably attributable to immune recovery related to potent ART.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827035\">",
"    <span class=\"h2\">",
"     Acquisition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillosis is caused by inhalation of fungal conidia (ie, spores) from the soil or air. Aspergilli are ubiquitous and have been cultured from air, dust, and environmental surfaces in hospitals. Immunocompromised patients have acquired aspergillosis in medical facilities with faulty ventilation systems or in healthcare clinics that are located near construction sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct inoculation onto the skin can also lead to cutaneous disease, which is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321613\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus infections occur most often in HIV-infected patients with AIDS with advanced immunosuppression (ie, CD4 cell counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    or in those patients with risk factors for the development of invasive disease, such as neutropenia or corticosteroid use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/3,8-11\">",
"     3,8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most important of these risk factors is severe neutropenia (&lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     ),",
"    </span>",
"    which can occur in the setting of advanced AIDS due to myelodysplasia, but is frequently secondary to medications that cause bone marrow suppression (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , antineoplastic agents,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    is also a risk factor for neutropenia and may be a consideration in resource-limited settings where this medication is still being used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=see_link\">",
"     \"Adverse effects of antiretroviral therapy in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other risk factors for aspergillosis include a prior history of one or more opportunistic infections (eg, Pneumocystis jirovecii pneumonia or cytomegalovirus infection), receipt of broad-spectrum antibiotics, alcohol or marijuana use, and underlying lung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/3,9,11,12\">",
"     3,9,11,12",
"    </a>",
"    ]. The risk of aspergillosis following Pneumocystis pneumonia may be related to two main factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Corticosteroids are routinely used as an adjunctive therapy in moderate to severe infection.",
"     </li>",
"     <li>",
"      Pneumocystis pneumonia can lead to abnormal architecture of the lung, creating an environment for Aspergillus colonization and subsequent invasion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to note that not all AIDS patients have a &ldquo;classic&rdquo; risk factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/14\">",
"     14",
"    </a>",
"    ]. Other immunologic defects associated with HIV infection, such as complement consumption due to high levels of circulating immune complexes, defective macrophage function, and impaired neutrophil chemotaxis and phagocytosis, may account for these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1827336\">",
"     'Pathogenesis and pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321620\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillus is a mould that is ubiquitous in the environment. There are over 200 aspergillus species described, of which at least 35 cause disease in humans. Of these, A. fumigatus is most common and is responsible for the vast majority of infections; in one large case series, A. fumigatus was identified in 95 percent of cases; A. flavus, A. niger, and A. terreus made up the remaining cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Microscopically, Aspergillus species have septate hyphae, with spherical, thick-walled conidia and smaller microconidia (",
"    <a class=\"graphic graphic_picture graphicRef70889 \" href=\"mobipreview.htm?28/20/28998\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827336\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled conidia reach small airways or alveolar spaces where hyphae may germinate and invade locally into lung tissue and vascular structures. Local invasion into blood vessels results in characteristic findings of aspergillosis, such as thrombosis leading to infarction and necrosis of surrounding tissue. Invasion of this pathogen into vascular structures can also lead to disseminated disease. Central nervous system disease may also occur secondary to local invasion from the sinuses or orbital spaces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although neutropenia is an important risk factor for invasive aspergillosis, animal and in vitro studies support a key role for alveolar macrophages in the early stages of host defense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/16\">",
"     16",
"    </a>",
"    ]. It has been demonstrated that corticosteroids impair macrophage killing of conidia and enable hyphal escape. However, in a mouse model, alveolar macrophage depletion did not lead to increased susceptibility to an intratracheal challenge with Aspergillus species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, neutrophil depletion prior to infection was associated with severe disease, while induction of neutropenia six hours after infection did not affect outcomes.",
"   </p>",
"   <p>",
"    These data suggest that neutrophils are essential in preventing conidial germination early in the disease process. AIDS patients also have well-described defects in neutrophil chemotaxis and binding, and impaired phagocytosis of macrophages, which may account for the association of neutropenia and the risk of aspergillosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321627\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive pulmonary aspergillosis (IPA) accounts for more than 80 percent of cases of aspergillus infection in HIV-infected patients. Disseminated infection can involve multiple organs, including the lungs, central nervous system, heart, kidney, and sinuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ]. Central nervous system involvement is usually manifested as a brain abscess, which usually occurs in association with pulmonary, sinus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    orbital involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/15\">",
"     15",
"    </a>",
"    ]. Neurologic manifestations can include headache, mental status changes, seizures, and cranial nerve abnormalities, depending on the location of the abscess.",
"   </p>",
"   <p>",
"    Pulmonary involvement is the most common finding in HIV-infected patients with disseminated aspergillosis affecting up to 75 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/10\">",
"     10",
"    </a>",
"    ]. Fever, cough, and shortness of breath are the most common symptoms in patients with invasive pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Chest pain and hemoptysis are less common, and usually associated with cavitary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8,18\">",
"     8,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest case series, published in 1998, included a review of all reported cases in HIV-infected patients in a MEDLINE search [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ]. Cases of &ldquo;definite IPA&rdquo; had clinical and or radiographic evidence of lung infection; invasive Aspergillus involvement was demonstrated by histology or with a positive culture obtained by percutaneous aspiration of the lung without growth of any other pathogen. Cases of &ldquo;probable IPA&rdquo; had radiographic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical evidence suggestive of IPA with a bronchoalveolar lavage from the lower respiratory tract positive for Aspergillus, without identification of any other pathogens. Among the patients with definite aspergillosis (n = 93), the mean CD4 count was 32",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    The most common symptoms among the patients with a definite diagnosis of IPA included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever (86 percent)",
"     </li>",
"     <li>",
"      Cough (70 percent)",
"     </li>",
"     <li>",
"      Dyspnea (66 percent)",
"     </li>",
"     <li>",
"      Pleuritic chest pain (27 percent)",
"     </li>",
"     <li>",
"      Generalized malaise, weight loss and anorexia (13 percent)",
"     </li>",
"     <li>",
"      CNS symptoms (11 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although aspergillus is an invasive infection, hemoptysis was uncommon and only reported in 5 percent of patients. In this series, the most common extrapulmonary system of involvement was the CNS (16 cases overall) followed by the kidneys (12 cases) and the heart (11 cases).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2840788\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific laboratory abnormalities are present in patients with aspergillosis. However, invasive aspergillosis usually occurs in patients with untreated advanced AIDS, or neutropenia, so the CD4 cell count is typically less than 50",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and the absolute neutrophil count may be low (&lt;500",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2840795\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three radiographic patterns are frequently described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cavitary lesions, predominantly upper lobe disease (36 percent)",
"     </li>",
"     <li>",
"      Focal alveolar infiltrates, including pleural based lesions (22 percent)",
"     </li>",
"     <li>",
"      Bilateral infiltrates, including diffuse nodular and reticulonodular or interstitial infiltrates (25 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chest radiographic findings in HIV-infected patients with aspergillosis are similar to those seen in HIV-negative immunocompromised hosts. Abnormalities can include nodular or cavitary disease; focal lobar infiltrates, sometimes bilateral or pleural based; and patchy, interstitial processes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1,19\">",
"     1,19",
"    </a>",
"    ]. In a study of 36 HIV-infected patients, the most common radiographic finding was upper lobe cavitary disease, present in 36 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8\">",
"     8",
"    </a>",
"    ]. Of note, no patients were observed as having the classic &ldquo;halo&rdquo; or &ldquo;air crescent&rdquo; signs often seen among neutropenic patients with hematologic malignancy. Pleural effusions are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827584\">",
"    <span class=\"h1\">",
"     OTHER FORMS OF PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much less commonly tracheobronchial or obstructive pulmonary aspergillosis may be seen; in one case series of 342 patients with Aspergillus infection, 7 percent involved the airways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ]. Aspergillomas have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321641\">",
"    <span class=\"h2\">",
"     Tracheobronchial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of tracheobronchial involvement have been described in HIV-infected patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive bronchial aspergillosis is a condition in which thick mucus plugs filled with Aspergillus are found in the airways, with little mucosal inflammation or invasion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8,11\">",
"       8,11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ulcerative tracheobronchitis is associated with focal fungal invasion of the tracheobronchial mucosa",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cartilage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pseudomembranous tracheobronchitis refers to extensive inflammation and invasion of the tracheobronchial tree with a pseudomembrane composed of necrotic debris and Aspergillus hyphae overlying the mucosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/14,21\">",
"       14,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with any of these forms of tracheobronchial disease tend to present with prominent dyspnea, cough, and wheezing. The chest radiograph may be normal or may reveal areas of atelectasis or parenchymal infiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1827603\">",
"    <span class=\"h2\">",
"     Aspergilloma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergilloma, which implies a non-invasive process of colonization by aspergillus in a prior cavity in the lung parenchyma, is uncommon in HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In a review of 342 cases of pulmonary aspergillosis, 14 patients were diagnosed with aspergillomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"     1",
"    </a>",
"    ]. Cases of aspergilloma have been described in patients with prior pneumatocele formation after recovery from Pneumocystis infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with aspergilloma are asymptomatic. When symptoms develop, they can include hemoptysis, chest pain, cough, fatigue, and weight loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=see_link\">",
"     \"Etiology and evaluation of hemoptysis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2840954\">",
"    <span class=\"h2\">",
"     Allergic bronchopulmonary aspergillosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This clinical entity is characterized by hypersensitivity to aspergillus species, most commonly A. fumigatus. This subacute respiratory illness has been rarely reported among HIV-infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/23\">",
"     23",
"    </a>",
"    ]. Presenting symptoms include cough, wheezing, sputum production, chest pain, hemoptysis and fever. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=see_link\">",
"     \"Allergic bronchopulmonary aspergillosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20321662\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aspergillosis is an important cause of morbidity and mortality in patients with untreated AIDS and advanced immunosuppression (eg, CD4 cell count &lt;50",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       ).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H20321599\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aspergillosis is caused by inhalation of fungal conidia (ie, spores) from the soil or air. Aspergilli are ubiquitous and have been cultured from air, dust, and environmental surfaces in hospitals. (See",
"      <a class=\"local\" href=\"#H1827035\">",
"       'Acquisition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive aspergillosis (IA) is an uncommon, although life-threatening, infection in patients with AIDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35270/abstract/2\">",
"       2",
"      </a>",
"      ]. Surveys from the United States demonstrate that since the introduction of potent antiretroviral therapy (ART) in 1996, the incidence of aspergillosis is low. (See",
"      <a class=\"local\" href=\"#H2840585\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neutropenia, corticosteroid use, and a history of prior lung disease or opportunistic infections are risk factors for the development of invasive aspergillosis. (See",
"      <a class=\"local\" href=\"#H20321613\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A. fumigatus is the most common species to cause disease. (See",
"      <a class=\"local\" href=\"#H20321620\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV-infected patients with aspergillosis usually present with pulmonary involvement, characterized by fever, cough, pleuritic chest pain and shortness of breath. Disseminated infection can involve multiple organs, including the central nervous system, heart, kidney, and sinuses. (See",
"      <a class=\"local\" href=\"#H20321627\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common radiographic abnormalities are nodular or cavitary lesions. (See",
"      <a class=\"local\" href=\"#H2840795\">",
"       'Radiographic manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/1\">",
"      Mylonakis E, Barlam TF, Flanigan T, Rich JD. Pulmonary aspergillosis and invasive disease in AIDS: review of 342 cases. Chest 1998; 114:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/2\">",
"      Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/3\">",
"      Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000; 31:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/4\">",
"      Tong KB, Lau CJ, Murtagh K, et al. The economic impact of aspergillosis: analysis of hospital expenditures across patient subgroups. Int J Infect Dis 2009; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/5\">",
"      Cornet M, Fleury L, Maslo C, et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002; 51:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/6\">",
"      Arnow PM, Sadigh M, Costas C, et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991; 164:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/7\">",
"      Roilides E, Farmaki E. Human immunodeficiency virus infection and cutaneous aspergillosis. Arch Dermatol 2000; 136:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/8\">",
"      Miller WT Jr, Sais GJ, Frank I, et al. Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. Chest 1994; 105:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/9\">",
"      Pursell KJ, Telzak EE, Armstrong D. Aspergillus species colonization and invasive disease in patients with AIDS. Clin Infect Dis 1992; 14:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/10\">",
"      Minamoto GY, Rosenberg AS. Fungal infections in patients with acquired immunodeficiency syndrome. Med Clin North Am 1997; 81:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/11\">",
"      Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/12\">",
"      Wallace JM, Lim R, Browdy BL, et al. Risk factors and outcomes associated with identification of Aspergillus in respiratory specimens from persons with HIV disease. Pulmonary Complications of HIV Infection Study Group. Chest 1998; 114:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/13\">",
"      Nash G, Irvine R, Kerschmann RL, Herndier B. Pulmonary aspergillosis in acquired immune deficiency syndrome: autopsy study of an emerging pulmonary complication of human immunodeficiency virus infection. Hum Pathol 1997; 28:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/14\">",
"      Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993; 95:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/15\">",
"      Mylonakis E, Paliou M, Sax PE, et al. Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review. Medicine (Baltimore) 2000; 79:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/16\">",
"      Dubourdeau M, Athman R, Balloy V, et al. Aspergillus fumigatus induces innate immune responses in alveolar macrophages through the MAPK pathway independently of TLR2 and TLR4. J Immunol 2006; 177:3994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/17\">",
"      Mircescu MM, Lipuma L, van Rooijen N, et al. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009; 200:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/18\">",
"      Thompson GR 3rd, Patterson TF. Pulmonary aspergillosis. Semin Respir Crit Care Med 2008; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/19\">",
"      Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/20\">",
"      Kemper CA, Hostetler JS, Follansbee SE, et al. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis 1993; 17:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/21\">",
"      Pervez NK, Kleinerman J, Kattan M, et al. Pseudomembranous necrotizing bronchial aspergillosis. A variant of invasive aspergillosis in a patient with hemophilia and acquired immune deficiency syndrome. Am Rev Respir Dis 1985; 131:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/22\">",
"      Addrizzo-Harris DJ, Harkin TJ, McGuinness G, et al. Pulmonary aspergilloma and AIDS. A comparison of HIV-infected and HIV-negative individuals. Chest 1997; 111:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/23\">",
"      Jain M. Allergic bronchopulmonary aspergillosis in an HIV-infected individual. Allergy Asthma Proc 2000; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/24\">",
"      Schouwink JH, Weigel HM, Blaauwgeers JL, Schreurs AJ. Aspergilloma formation in a pneumatocele associated with Pneumocystis carinii pneumonia. AIDS 1997; 11:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35270/abstract/25\">",
"      Torrents C, Alvarez-Castells A, de Vera PV, et al. Postpneumocystis aspergilloma in AIDS: CT features. J Comput Assist Tomogr 1991; 15:304.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13968 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35270=[""].join("\n");
var outline_f34_28_35270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20321662\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20321599\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20321606\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2840585\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1827035\">",
"      Acquisition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20321613\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20321620\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1827336\">",
"      PATHOGENESIS AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20321627\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2840788\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2840795\">",
"      RADIOGRAPHIC MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1827584\">",
"      OTHER FORMS OF PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20321641\">",
"      Tracheobronchial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1827603\">",
"      Aspergilloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2840954\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20321662\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/13968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/13968|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/20/28998\" title=\"picture 1\">",
"      Histopathology Aspergillus spp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/34/10794?source=related_link\">",
"      Adverse effects of antiretroviral therapy in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/58/11178?source=related_link\">",
"      Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/24/14727?source=related_link\">",
"      Etiology and evaluation of hemoptysis in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35271="Pneumothorax and air travel";
var content_f34_28_35271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumothorax and air travel",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Lawrence C Mohr, MD, FACP, FCCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35271/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/28/35271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that over one billion passengers travel by air each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although up to 5 percent of passengers have some form of disability or chronic medical illness, in-flight emergencies are infrequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/4\">",
"     4",
"    </a>",
"    ]. Only one of every 39,000 passengers (0.003 percent) experiences an in-flight medical problem serious enough to come to the attention of emergency personnel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Death during commercial flight is even rarer. During the year July 1998 to July 1999, the Federal Aviation Association collected medical events data, and 43 deaths occurred in-flight out of 600 million passengers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence, pathogenesis, and management of in-flight and previous",
"    <span class=\"nowrap\">",
"     pneumothorax/pneumomediastinum",
"    </span>",
"    <span class=\"nowrap\">",
"     (PTX/PMD)",
"    </span>",
"    will be reviewed here. Pre-flight medical assessment, the prevention of in-flight hypoxemia in patients with underlying lung disease, and the management of spontaneous PTX are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=see_link\">",
"     \"Patient assessment for air travel\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact incidence of",
"    <span class=\"nowrap\">",
"     PTX/PMD",
"    </span>",
"    during commercial air travel is unknown due to non-standardized reporting requirements for in-flight medical emergencies. Anecdotal reports of in-flight pneumothoraces have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, in-flight PTX must be exceedingly rare, since it is not mentioned in most reports addressing in-flight emergencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/5,6,11-13\">",
"     5,6,11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few reports have described the experience of individuals at high risk for pulmonary complications during air travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 1115 passengers referred to an airline medical advisory service for pre-flight evaluation, 704 had COPD or another pulmonary disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/14\">",
"       14",
"      </a>",
"      ]. Over 90 percent were \"cleared\" for transport. None of those cleared for air travel was known to have experienced a significant in-flight medical problem.",
"     </li>",
"     <li>",
"      Twenty of 21 patients flying from Israel to Europe and the United States for lung transplantation or thromboendarterectomy arrived safely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/15\">",
"       15",
"      </a>",
"      ]. However, one patient, who was hemodynamically unstable and requiring vasopressors and mechanical ventilation with a high concentration of oxygen (FIO2 = 0.80), died of hypoxemia and shock after six hours of a relatively stable flight, presumably not due to a pneumothorax.",
"     </li>",
"     <li>",
"      Between 1986 and 1988, the Federal Aviation Administration (FAA) required air carriers to maintain records of all medical emergencies. A total of 2322 emergencies were documented during the two year period. Unfortunately, case descriptions were limited and the diagnoses were not necessarily confirmed medically. Only one definite and one possible PTX were reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In comparison, the reported incidence of spontaneous PTX not associated with air travel in the general population has ranged from 7 to",
"    <span class=\"nowrap\">",
"     18/100,000",
"    </span>",
"    per year for males and 1 to",
"    <span class=\"nowrap\">",
"     6/100,000",
"    </span>",
"    per year for females [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumomediastinum (PMD) during air travel has been described in a few case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Precipitating factors have included upper respiratory tract infection, multiple Valsalva maneuvers in-flight and rupture of a bronchogenic cyst, but at least one PMD occurred in-flight without an apparent precipitating event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As altitude increases, both barometric pressure and the atmospheric partial pressure of oxygen (PiO2) decrease exponentially. Thus, atmospheric pressure and PiO2 are significantly lower at a typical aircraft cruising altitude of 35,000 feet than they are at sea level l (",
"    <a class=\"graphic graphic_table graphicRef77616 \" href=\"mobipreview.htm?31/21/32092\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/22\">",
"     22",
"    </a>",
"    ]. Pressurization of the cabin on commercial airliners limits the decrease in air pressure, allowing aircraft to cruise at altitudes up to 40,000 feet (12,192 m) with cabin pressures around 565 mmHg, instead of the actual atmospheric pressure of 141 mmHg at that altitude (",
"    <a class=\"graphic graphic_table graphicRef77616 \" href=\"mobipreview.htm?31/21/32092\">",
"     table 1",
"    </a>",
"    ). Barometric pressure at sea level is approximately 760 mmHg.",
"   </p>",
"   <p>",
"    Boyle's law states that the volume of a gas is inversely proportional to the pressure to which it is exposed. Thus, as barometric pressure falls in the aircraft cabin during the ascent, trapped air in any non-communicating body cavity (eg, non-communicating PTX, lung bleb, lung bulla, lung cyst, paranasal sinuses) will expand. Expansion of gas in the lungs is also increased by the high moisture content [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. It is estimated that the volume of air in a non-communicating body cavity, such as a PTX, will increase by approximately 38 percent upon ascent from sea level to the maximum \"cabin altitude\" of 8,000 feet (2438 m) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two main factors that might predispose certain individuals to PTX during air travel:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Air trapping due to airway obstruction. Among patients who experienced a PTX in-flight, an increase in respiratory tract symptoms was noted in the days prior to air travel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/8\">",
"       8",
"      </a>",
"      ]. Perhaps mucous plugging of small airways caused increased air trapping, and expansion of the trapped air during the ascent to altitude ruptured the alveolar wall causing a PTX. The low PiO2 at high altitude may further worsen airway obstruction and air trapping in patients with COPD by causing hypoxic bronchoconstriction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Expansion of air trapped in noncommunicating blebs, bullae, and intrapulmonary cysts. During ascent to altitude, the expansion of trapped air can lead to rupture and cause a PTX or PMD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/24,29\">",
"       24,29",
"      </a>",
"      ]. Further air expansion can convert a PTX to a tension PTX, resulting in life-threatening cardiopulmonary compromise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/26,30,31\">",
"       26,30,31",
"      </a>",
"      ]. Expansion of blebs at reduced ambient barometric pressure has been demonstrated radiographically [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/24\">",
"       24",
"      </a>",
"      ]. Even without rupture, the expansion of trapped air in large non-communicating blebs, bullae, or cysts can potentially cause compression of functional lung, mediastinal shift, and circulatory compromise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/7,9\">",
"       7,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regulatory government agencies, such as the Federal Aviation Administration, have requirements specifying that commercial aircraft cabins be pressurized to simulate an altitude (so&ndash;called cabin altitude) below 8000 feet (2438 m) and allowing only brief diversions to a cabin altitude of 10,000 feet (3048 m) for safety (eg, to avoid adverse weather). A &ldquo;cabin altitude&rdquo; of 8000 feet maintains the cabin pressure at 565 mmHg or greater. Different types of aircraft can achieve different degrees of pressurization, but most aircraft can be pressurized to 400 or 450 mmHg above the actual atmospheric pressure outside the aircraft (",
"    <a class=\"graphic graphic_table graphicRef73332 \" href=\"mobipreview.htm?34/31/35323\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High performance aircraft pose a special problem due to the unique pulmonary effects of high gravitational forces (G-forces). Very low intrapleural pressures (-32 cmH2O) over the apical surfaces of the lung have been noted at high G-forces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/30\">",
"     30",
"    </a>",
"    ]. PTX, mediastinal emphysema, and hemoptysis can result from these disruptive forces [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/30,32,33\">",
"     30,32,33",
"    </a>",
"    ]. High G-forces do not occur during commercial air travel, but are important considerations for military aviators and test pilots who fly high performance aircraft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885628620\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PTX and PMD may occur together or independently.",
"   </p>",
"   <p>",
"    Symptoms of PTX occurring at altitude are the same as those occurring at ground level. Chest pain (sometimes pleuritic) and dyspnea have been reported in confirmed cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/9,11-13\">",
"     9,11-13",
"    </a>",
"    ]. When the PTX is large, characteristic physical findings include decreased chest excursion on the affected side, diminished breath sounds, and hyperresonant percussion. Subcutaneous emphysema may be present. Tension PTX is a life-threatening emergency that may complicate a spontaneous PTX. Clinical manifestations include tachypnea, tachycardia, hypoxemia, and hypotension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H7#H7\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms and signs of a pneumomediastinum include chest pain (typically retrosternal), throat pain, dyspnea, and subcutaneous emphysema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The key finding on physical examination is subcutaneous emphysema, usually over the neck and shoulders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67683858\">",
"    <span class=\"h1\">",
"     IN-FLIGHT MANAGEMENT OF PTX/PMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop symptoms and signs of a PTX or PMD while in-flight, administration of supplemental oxygen is the most important intervention. For patients with respiratory distress, emergency landing at the nearest airport will allow prompt evaluation and insertion of a chest tube, if needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885628795\">",
"    <span class=\"h1\">",
"     AIR TRAVEL WITH A PTX/PMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, the presence of a PTX at the time of a flight has been considered an absolute contraindication to air travel, and we still advise not travelling until complete resolution of a pneumothorax has been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the possibility that selected patients with a small, stable pneumothorax may be able to travel safely for a short flight was examined in an observational study of 50 patients with a PTX following transthoracic needle aspiration biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/36\">",
"     36",
"    </a>",
"    ]. Air travel within four days of a chest radiograph showing a residual PTX was not associated with any need for in-flight medical attention and less than 8 percent experienced minor chest symptoms during air travel. Further study is needed to fully evaluate the safety of short-duration air travel for patients with small, stable pneumothoraces, but without other underlying lung disease.",
"   </p>",
"   <p>",
"    A separate report describes an uneventful flight of a patient with a PTX who had a chest tube in place with a unidirectional flutter valve (Heimlich valve) attached [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/37\">",
"     37",
"    </a>",
"    ]. Emergent air travel of patients with pneumothoraces has been reported during war time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/38\">",
"     38",
"    </a>",
"    ]. Two of three such subjects who were transported at more than 9000 feet in an unpressurized cabin tolerated the trip; one died of bilateral pneumothoraces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H885628459\">",
"    <span class=\"h1\">",
"     TIMING OF AIR TRAVEL AFTER PTX/PMD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal length of time to wait after resolution of a",
"    <span class=\"nowrap\">",
"     PTX/PMD",
"    </span>",
"    before travelling by air is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/39\">",
"     39",
"    </a>",
"    ]. For patients with a prior PTX, the decision about air travel must be made on an individual basis, taking into consideration the likelihood of recurrence and how well the patient would tolerate a subsequent PTX. For example, a patient with relatively normal lung parenchyma could be permitted to fly two weeks after resolution of an iatrogenic PTX. However, air travel may be contraindicated in a patient with severe bullous emphysema, limited cardiopulmonary reserve, and a prior spontaneous PTX. The type of treatment the patient received (eg, simple aspiration, tube thoracostomy, chemical or mechanical pleurodesis) likely influences the risk of recurrence during air travel, although this has not been studied. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=see_link&amp;anchor=H18#H18\">",
"     \"Primary spontaneous pneumothorax in adults\", section on 'Recurrence prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H12#H12\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'After initial stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience in a small number of patients suggests that air travel should be avoided for at least two weeks following resolution of a traumatic PTX. As an example, among 12 patients with a recent traumatic PTX, those who waited for at least 14 days after radiographic resolution of the PTX were asymptomatic in-flight, while one of two patients who flew sooner than 14 days developed respiratory distress suggestive of a recurrent PTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some experts recommend that stable patients with bullous emphysema who have had a previous PTX wait at least one year from the date of radiographic resolution of the PTX before considering air travel, although data supporting this advice are lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050903\">",
"    <span class=\"h1\">",
"     TIMING OF AIR TRAVEL AFTER CARDIOTHORACIC SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ideal duration of time to delay air travel after cardiothoracic surgery is unknown. In a survey of 68 thoracic surgeons, 44 percent allowed their patients to fly after a variable length of time (up to 42 days) after complete radiographic resolution of a postoperative PTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/39\">",
"     39",
"    </a>",
"    ]. Seventy-seven percent allowed their patients to fly without delay following mediastinoscopy, even with a residual PMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/39\">",
"     39",
"    </a>",
"    ]. In this survey, the only adverse in-flight event reported was a case of thoracic pain during ascent of the air craft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050519\">",
"    <span class=\"h1\">",
"     DISEASE-SPECIFIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous emphysema, idiopathic pulmonary fibrosis, lymphangioleiomyomatosis, and intraparenchymal lung cysts have been associated with an increased risk of PTX and PMD. Limited data are available to guide recommendations for these patients regarding air travel, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050526\">",
"    <span class=\"h2\">",
"     Bullous emphysema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large number of travellers with COPD combined with the low overall rate of PTX suggests that the absolute risk of in-flight PTX is low in these patients. However, patients with bullous emphysema likely have an increased risk of rupture of a bulla and development of a PTX during air travel, especially if they have had a previous PTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/26,27,41\">",
"     26,27,41",
"    </a>",
"    ]. In addition, a PTX in such patients could lead to life-threatening cardiopulmonary compromise as a result of a low baseline arterial oxygen tension (PaO2) and a lack of sufficient ventilatory reserve to hyperventilate in response to hypoxemia. Data are insufficient to calculate the exact risk of spontaneous secondary PTX for patients with bullous emphysema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H3#H3\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'Chronic obstructive pulmonary disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with COPD or bullous emphysema should be advised to postpone air travel should they develop an exacerbation of COPD. Chest imaging to exclude a PTX may be appropriate for patients who develop an increase in dyspnea just prior to air travel, as the presence of a PTX would be an absolute contraindication to air travel. A history of a prior spontaneous PTX in a patient with COPD likely increases the risk of in-flight PTX, as the risk of a second spontaneous PTX (without air travel) is approximately 50 percent over three years, unless the patient undergoes some form of pleurodesis. Some experts advise that patients with COPD delay air travel for one year after a spontaneous PTX. (See",
"    <a class=\"local\" href=\"#H885628459\">",
"     'Timing of air travel after PTX/PMD'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H12#H12\">",
"     \"Secondary spontaneous pneumothorax in adults\", section on 'After initial stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with emphysema should be assessed for potential in-flight hypoxemia and supplemental oxygen supplied when necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link&amp;anchor=H5#H5\">",
"     \"Traveling with oxygen aboard commercial air carriers\", section on 'Screening for in-flight hypoxemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050533\">",
"    <span class=\"h2\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic pulmonary fibrosis (IPF, also known as usual interstitial pneumonitis) and sarcoidosis are two of the more common types of interstitial lung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=see_link&amp;anchor=H3#H3\">",
"     \"Idiopathic interstitial pneumonias: Clinical manifestations and pathology\", section on 'Usual interstitial pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The natural history and clinical presentation of spontaneous PTX and PMD were examined in 72 patients with IPF who underwent chest computed tomography (CT) at a single institution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/42\">",
"     42",
"    </a>",
"    ]. Of the five patients with a PTX, four had acute dyspnea and pleuritic chest pain and one had no acute change in respiratory status. Three of the four patients with a PMD had acute symptoms. Three of the PTX resolved by five months, while two loculated PTX were unchanged after five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/42\">",
"     42",
"    </a>",
"    ]. Thus, PTX and PMD may be asymptomatic and may be chronic in patients with IPF. The risk of in-flight PTX was examined in 76 patients with IPF who had a chest CT scan after 159 trips by air, none had developed a PTX or PMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In sarcoidosis, granulomatous involvement of the lung interstitium and airways can lead to air trapping, pulmonary fibrosis, and lung cyst formation, all of which might theoretically increase the risk of altitude-related PTX and PMD. Among 92 patients with sarcoidosis who had chest CT scans after a total of 121 trips by air, none developed a PTX or PMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, air travel appears reasonably safe for patients with interstitial lung disease. However, a preflight chest computed tomography (CT) may be warranted in those with a history of a PTX or PMD within the previous six months or with an intercurrent exacerbation of respiratory symptoms.",
"   </p>",
"   <p>",
"    Patients with moderate to advanced interstitial lung disease should be assessed for potential in-flight hypoxemia and supplemental oxygen supplied when necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link&amp;anchor=H5#H5\">",
"     \"Traveling with oxygen aboard commercial air carriers\", section on 'Screening for in-flight hypoxemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050540\">",
"    <span class=\"h2\">",
"     Lymphangioleiomyomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary lymphangioleiomyomatosis (LAM) is characterized by diffuse, cystic dilatation of the terminal airspaces, presumably due to proliferation of atypical smooth muscle cells causing airway obstruction. Spontaneous PTX is a common complication of LAM, occurring in approximately 50 percent. Despite the high overall frequency of PTX, the risk of PTX during air flight is low (2 to 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary lymphangioleiomyomatosis\", section on 'Air travel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with LAM, a history of a previous PTX is a risk factor for subsequent PTX. However, in 9 patients with a chronic PTX due to LAM, the size of the PTX did not significantly increase after air travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"     43",
"    </a>",
"    ]. The following advice has been suggested for patients with LAM who are contemplating air travel:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Air travel is generally safe, if the patient has no clinical or radiological evidence of PTX and no history of a recent PTX.",
"     </li>",
"     <li>",
"      The relatively low risk of a new PTX during air travel may be even lower in those patients with small lung cysts and mild disease.",
"     </li>",
"     <li>",
"      The presence of chronic, stable pneumothoraces may not pose additional risks for LAM patients during air travel, although additional data is needed for confirmation.",
"     </li>",
"     <li>",
"      Acute symptoms suspicious for PTX should prompt appropriate radiological imaging (eg, chest radiograph",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      computed tomography) prior to air travel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H228050547\">",
"    <span class=\"h2\">",
"     Intrapulmonary bronchogenic cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapulmonary bronchogenic cysts have rarely been associated with PTX and PMD during ascent to altitude by aircraft or train, sometimes in association with cerebral air embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. The incidence of PTX and PMD during air travel among patients with congenital intrapulmonary lung cysts is not known. However, among 15 patients with lung cysts complicating IPF who had a chest CT scan shortly after air travel, none had developed a PTX or PMD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/30/40418?source=see_link\">",
"       \"Patient information: Pneumothorax (collapsed lung) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development of a pneumothorax (PTX) or pneumomediastinum (PMD) during air travel is infrequent. However, patients with certain underlying lung diseases may be at increased risk for development of pneumothorax. Patients with poor respiratory reserve may not tolerate additional compromise to their lung function should a PTX occur. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of PTX and PMD follows Boyle&rsquo;s law: the volume of a gas is inversely proportional to the pressure to which it is exposed. Thus, as an aircraft ascends during flight, barometric pressure falls, and trapped air expands in non-communicating body cavities (eg, non-communicating pneumothoraces, lung blebs, lung bullae, lung cysts, paranasal sinuses). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical symptoms and signs of a PTX are chest pain (sometimes pleuritic) and dyspnea. Symptoms and signs of a PMD include chest pain (typically retrosternal), throat pain, dyspnea, and subcutaneous emphysema. (See",
"      <a class=\"local\" href=\"#H885628620\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop symptoms and signs of a PTX or PMD while in-flight, administration of supplemental oxygen is the most important intervention. For patients with respiratory distress, emergency landing at the nearest airport will allow prompt evaluation and insertion of a chest tube, if needed. (See",
"      <a class=\"local\" href=\"#H67683858\">",
"       'In-flight management of PTX/PMD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A current PTX is a contraindication to commercial air travel. Patients who have a thoracostomy tube in place with a unidirectional valve (Heimlich valve) for decompression may be able to tolerate air travel when medically necessary. (See",
"      <a class=\"local\" href=\"#H885628795\">",
"       'Air travel with a PTX/PMD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those patients with a history of a prior PTX, the decision about air travel must be made on an individual basis, taking into consideration the likelihood of recurrence and how well the patient would tolerate a subsequent PTX. For example, a patient with relatively normal lung parenchyma could be permitted to fly two weeks after resolution of an iatrogenic PTX. However, air travel may be contraindicated in a patient with severe bullous emphysema, limited cardiopulmonary reserve, and a prior spontaneous PTX. (See",
"      <a class=\"local\" href=\"#H885628459\">",
"       'Timing of air travel after PTX/PMD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, air travel is postponed for at least two weeks following radiographic resolution of a traumatic or spontaneous PTX. For patients with underlying diseases that may predispose to recurrent PTX (eg, bullous emphysema, interstitial lung disease, lymphangioleiomyomatosis, intraparenchymal lung cysts), a longer delay or pleurodesis may be appropriate before air travel. (See",
"      <a class=\"local\" href=\"#H885628459\">",
"       'Timing of air travel after PTX/PMD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H228050519\">",
"       'Disease-specific management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=see_link&amp;anchor=H12#H12\">",
"       \"Secondary spontaneous pneumothorax in adults\", section on 'After initial stabilization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ideal duration of time to delay air travel after cardiothoracic surgery is unknown. Most clinicians advise waiting three to four weeks after resolution of any postsurgical PTX. For patients who are stable after a mediastinoscopy, delaying air travel is usually not necessary in the absence of underlying lung disease. (See",
"      <a class=\"local\" href=\"#H228050903\">",
"       'Timing of air travel after cardiothoracic surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bullous emphysema, interstitial lung disease, lymphangioleiomyomatosis, and intraparenchymal lung cysts have been associated with an increased risk of spontaneous PTX and PMD. Limited data are available to guide air travel recommendations for these patients. For those without a previous PTX, we typically obtain a pre-flight chest radiograph or computed tomography (CT) scan if the patient experiences an increase in dyspnea or onset of chest pain in the days to weeks prior to air travel. (See",
"      <a class=\"local\" href=\"#H228050519\">",
"       'Disease-specific management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most experts advise patients to avoid air travel during an exacerbation of chronic obstructive pulmonary disease (COPD), due to a theoretic increase in risk of PTX from increased air trapping associated with an exacerbation. (See",
"      <a class=\"local\" href=\"#H228050526\">",
"       'Bullous emphysema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with chronic cardiopulmonary disorders should be evaluated for in-flight oxygen therapy prior to air travel. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/1\">",
"      Gendreau MA, DeJohn C. Responding to medical events during commercial airline flights. N Engl J Med 2002; 346:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/2\">",
"      Goodwin T. In-flight medical emergencies: an overview. BMJ 2000; 321:1338.",
"     </a>",
"    </li>",
"    <li>",
"     British Thoracic Society. Managing passengers with respiratory disease planning air travel file://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Air%20Travel/Guidelines/FlightRevision04.pdf (Accessed on October 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/4\">",
"      Gong H Jr. Air travel and oxygen therapy in cardiopulmonary patients. Chest 1992; 101:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/5\">",
"      Cummins RO, Schubach JA. Frequency and types of medical emergencies among commercial air travelers. JAMA 1989; 261:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/6\">",
"      Speizer C, Rennie CJ 3rd, Breton H. Prevalence of in-flight medical emergencies on commercial airlines. Ann Emerg Med 1989; 18:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/7\">",
"      Aerospace Medical Association Medical Guidelines Task Force. Medical Guidelines for Airline Travel, 2nd ed. Aviat Space Environ Med 2003; 74:A1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/8\">",
"      Flux M, Dille JR. Inflight spontaneous pneumothorax: a case report. Aerosp Med 1969; 40:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/9\">",
"      Neidhart P, Suter PM. Pulmonary bulla and sudden death in a young aeroplane passenger. Intensive Care Med 1985; 11:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/10\">",
"      AMDUR RD. Recurrent spontaneous pneumothorax caused by aerial flight; report of case. J Aviat Med 1956; 27:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/11\">",
"      Lyznicki JM, Williams MA, Deitchman SD, et al. Inflight medical emergencies. Aviat Space Environ Med 2000; 71:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/12\">",
"      Jagoda A, Pietrzak M. Medical emergencies in commercial air travel. Emerg Med Clin North Am 1997; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/13\">",
"      Rosenberg CA, Pak F. Emergencies in the air: problems, management, and prevention. J Emerg Med 1997; 15:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/14\">",
"      Gong H Jr, Mark JA, Cowan MN. Preflight medical screenings of patients. Analysis of health and flight characteristics. Chest 1993; 104:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/15\">",
"      Kramer MR, Jakobson DJ, Springer C, Donchin Y. The safety of air transportation of patients with advanced lung disease. Experience with 21 patients requiring lung transplantation or pulmonary thromboendarterectomy. Chest 1995; 108:1292.",
"     </a>",
"    </li>",
"    <li>",
"     Hordinsky, JR, George MH. Response capability during civil air carrier inflight medical emergencies (Report No. DOT/FAA/AM-91/3). National Technical Information Service, Springfield, VA 22161.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/17\">",
"      Melton LJ 3rd, Hepper NG, Offord KP. Influence of height on the risk of spontaneous pneumothorax. Mayo Clin Proc 1981; 56:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/18\">",
"      Bense L, Eklund G, Wiman LG. Smoking and the increased risk of contracting spontaneous pneumothorax. Chest 1987; 92:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/19\">",
"      Nicol E, Davies G, Jayakumar P, Green ND. Pneumopericardium and pneumomediastinum in a passenger on a commercial flight. Aviat Space Environ Med 2007; 78:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/20\">",
"      Morgan J, Sadler MA, Yeghiayan P. Spontaneous pneumomediastinum in a patient with recent air travel. Emerg Radiol 2007; 14:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/21\">",
"      Jung S, Wiest R, Frigerio S, et al. Cerebral air embolism caused by a bronchogenic cyst. Pract Neurol 2010; 10:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/22\">",
"      Cottrell JJ. Altitude exposures during aircraft flight. Flying higher. Chest 1988; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/23\">",
"      Zaugg M, Kaplan V, Widmer U, et al. Fatal air embolism in an airplane passenger with a giant intrapulmonary bronchogenic cyst. Am J Respir Crit Care Med 1998; 157:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/24\">",
"      PARKER GW, STONEHILL RB. Further considerations of the roentgenologic evaluation of flying personnel at simulated altitude. Aerosp Med 1961; 32:501.",
"     </a>",
"    </li>",
"    <li>",
"     Fundamentals of Aerospace Medicine, Dehart RL (Ed), Lea and Febiger, Philadelphia 1985. p.152.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/26\">",
"      Mohr LC. Hypoxia during air travel in adults with pulmonary disease. Am J Med Sci 2008; 335:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/27\">",
"      British Thoracic Society Standards of Care Committee. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2002; 57:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/28\">",
"      Astin TW, Penman RW. Airway obstruction due to hypoxemia in patients with chronic lung disease. Am Rev Respir Dis 1967; 95:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/29\">",
"      DERMKSIAN G, LAMB LE. Spontaneous pneumothorax in apparently healthy flying personnel. Ann Intern Med 1959; 51:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/30\">",
"      Fuchs HS. Idiopathic spontaneous pneumothorax and flying. With particular reference to the etiological role of decreased atmospheric pressure, pressure breathing, increased gravitational forces, and anti-G-suit action. Aerosp Med 1967; 38:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/31\">",
"      Medical aspects of transportation aboard commercial aircraft. AMA commission on emergency medical services. JAMA 1982; 247:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/32\">",
"      Robb DJ. Cases from the aerospace medicine residents' teaching file. Case H57. Complete spontaneous pneumothorax in-flight in an F-16 pilot during a high-G maneuver. Aviat Space Environ Med 1994; 65:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/33\">",
"      McCormick TJ, Lyons TJ. Medical causes of in-flight incapacitation: USAF experience 1978-1987. Aviat Space Environ Med 1991; 62:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/34\">",
"      Caceres M, Ali SZ, Braud R, et al. Spontaneous pneumomediastinum: a comparative study and review of the literature. Ann Thorac Surg 2008; 86:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/35\">",
"      Macia I, Moya J, Ramos R, et al. Spontaneous pneumomediastinum: 41 cases. Eur J Cardiothorac Surg 2007; 31:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/36\">",
"      Tam A, Singh P, Ensor JE, et al. Air travel after biopsy-related pneumothorax: is it safe to fly? J Vasc Interv Radiol 2011; 22:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/37\">",
"      Stonehill RB, Fess SW. Commercial air transportation of a patient recovering from pneumothorax. Chest 1973; 63:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/38\">",
"      Haid MM, Paladini P, Maccherini M, et al. Air transport and the fate of pneumothorax in pleural adhesions. Thorax 1992; 47:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/39\">",
"      Szymanski TJ, Jaklitsch MT, Jacobson F, et al. Expansion of postoperative pneumothorax and pneumomediastinum: determining when it is safe to fly. Aviat Space Environ Med 2010; 81:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/40\">",
"      Cheatham ML, Safcsak K. Air travel following traumatic pneumothorax: when is it safe? Am Surg 1999; 65:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/41\">",
"      Lippert HL, Lund O, Blegvad S, Larsen HV. Independent risk factors for cumulative recurrence rate after first spontaneous pneumothorax. Eur Respir J 1991; 4:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/42\">",
"      Franquet T, Gim&eacute;nez A, Torrubia S, et al. Spontaneous pneumothorax and pneumomediastinum in IPF. Eur Radiol 2000; 10:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35271/abstract/43\">",
"      Taveira-DaSilva AM, Burstein D, Hathaway OM, et al. Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. Chest 2009; 136:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6705 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-F9050627AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35271=[""].join("\n");
var outline_f34_28_35271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H885628620\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67683858\">",
"      IN-FLIGHT MANAGEMENT OF PTX/PMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H885628795\">",
"      AIR TRAVEL WITH A PTX/PMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H885628459\">",
"      TIMING OF AIR TRAVEL AFTER PTX/PMD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H228050903\">",
"      TIMING OF AIR TRAVEL AFTER CARDIOTHORACIC SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H228050519\">",
"      DISEASE-SPECIFIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228050526\">",
"      Bullous emphysema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228050533\">",
"      Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228050540\">",
"      Lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H228050547\">",
"      Intrapulmonary bronchogenic cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/6705\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/6705|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/21/32092\" title=\"table 1\">",
"      Gas properties at altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/31/35323\" title=\"table 2\">",
"      Aircraft cabin pressurization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/23/4474?source=related_link\">",
"      Idiopathic interstitial pneumonias: Clinical manifestations and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/30/40418?source=related_link\">",
"      Patient information: Pneumothorax (collapsed lung) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/30/4586?source=related_link\">",
"      Pulmonary lymphangioleiomyomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35272="Functional dyspepsia";
var content_f34_28_35272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Functional dyspepsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     George F Longstreth, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35272/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/28/35272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspepsia is a common symptom with an extensive differential diagnosis and a heterogeneous pathophysiology. It occurs in approximately 25 percent of the population each year, but most affected people do not seek medical care.",
"   </p>",
"   <p>",
"    Approximately 25 percent of patients with dyspepsia have an underlying organic cause. However, up to 75 percent of patients have functional (idiopathic or nonulcer) dyspepsia with no underlying cause on diagnostic evaluation.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of the pathophysiology and treatment of functional dyspepsia. The definition, etiology, and general approach to the evaluation and management of the patient with dyspepsia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations for the management of functional dyspepsia are largely consistent with the American Gastroenterological Association guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the Rome III criteria, functional dyspepsia is defined as the presence of one or more of the following: postprandial fullness, early satiation, epigastric pain or burning and no evidence of structural disease (including at upper endoscopy) to explain the symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/2\">",
"     2",
"    </a>",
"    ]. While patients with these symptoms and a negative diagnostic evaluation likely have functional dyspepsia, according to the Rome III guidelines, the criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis.",
"   </p>",
"   <p>",
"    Functional dyspepsia is classified into postprandial distress syndrome and epigastric pain syndrome (",
"    <a class=\"graphic graphic_table graphicRef87623 \" href=\"mobipreview.htm?36/41/37532\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While several mechanisms have been proposed, the pathogenesis of functional dyspepsia remains unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gastric motility and compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several motility disorders have been reported in patients with dyspepsia. These include delayed gastric emptying, antral hypomotility, gastric dysrhythmias, and impaired gastric accommodation in response to a meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these findings are noted in only a subset of patients with dyspepsia. As examples, delayed gastric emptying and antral hypomotility are found in only 30 percent of patients with dyspepsia and up to 10 percent of patients with dyspepsia have fast gastric emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=see_link\">",
"     \"Etiology and diagnosis of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Visceral hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral hypersensitivity is characterized by a lowered threshold for induction of pain in the presence of normal gastric compliance. Several studies have demonstrated visceral hypersensitivity in patients with functional dyspepsia that occurs independently of delayed gastric emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Both mechanoreceptor dysfunction and aberrant processing of afferent input in the spinal cord or brain may play a role in the pathophysiology of visceral hypersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, the sensorial responses and the gastric tone responses to either gastric accommodation or to cold stress were measured in 20 patients with functional dyspepsia and 20 healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/11\">",
"     11",
"    </a>",
"    ]. Gastric compliance was similar in patients and controls; however, gastric distention elicited more upper abdominal discomfort in the patients with dyspepsia. Similar findings were noted in another observational study in which reduced perceptual thresholds or altered pain referral were found in 87 percent of patients with functional dyspepsia as compared with 20 percent of patients with organic causes of dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with dyspepsia may also have increased chemosensitivity. In one study, patients with functional dyspepsia were significantly more likely to have nausea in response to acid infusion into the duodenal bulb as compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with functional dyspepsia also had decreased duodenal motor activity in the fasting state, resulting in decreased clearance of infused acid from the proximal duodenum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Helicobacter pylori infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are several hypotheses with regard to the role of",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    (",
"    <em>",
"     H. pylori",
"    </em>",
"    ) infection in the pathogenesis of functional dyspepsia, the mechanism remains unclear. &nbsp;",
"   </p>",
"   <p>",
"    <em>",
"     H. pylori",
"    </em>",
"    may cause altered smooth muscle dysfunction due to the induction of an inflammatory response or by the initiation of an antibody response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, studies have not found an association between",
"    <em>",
"     H. pylori",
"    </em>",
"    and abnormal gastric motor function in patients with functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4809?source=see_link\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The inflammatory response induced by",
"    <em>",
"     H. pylori",
"    </em>",
"    may lower the discomfort threshold to gastric distension by causing alterations in the enteric or central nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/17\">",
"     17",
"    </a>",
"    ]. However, in at least one study,",
"    <em>",
"     H. pylori",
"    </em>",
"    positive and negative patients with functional dyspepsia had no difference in the perception of mechanically-induced gastric distension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence from randomized controlled trials that eradication of H. pylori results in relief of dyspepsia in a minority of patients. However, studies have failed to establish a temporal relationship between",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and functional dyspepsia, or the association of",
"    <em>",
"     H. pylori",
"    </em>",
"    with a specific symptom complex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/17\">",
"     17",
"    </a>",
"    ]. Therefore, relief of dyspepsia may reflect other factors such as cure of unrecognized peptic ulcer disease in patients misdiagnosed with functional (nonulcer) dyspepsia. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Altered gut microbiome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in the upper gastrointestinal tract microbiome may result in the development of dyspepsia, although this has not been directly, formally evaluated.",
"   </p>",
"   <p>",
"    This hypothesis is supported by the observation that dyspeptic symptoms are more likely to occur after an episode of gastroenteritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In one study, patients were noted to have persistent symptoms eight years after exposure to a waterborne outbreak of bacterial dysentery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/23\">",
"     23",
"    </a>",
"    ]. It has also been hypothesized that the efficacy of",
"    <em>",
"     H. pylori",
"    </em>",
"    therapy in improving symptoms of functional dyspepsia is due to the impact on the gut microbiome rather than the eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An association between functional dyspepsia and increased duodenal eosinophilia has been reported, with an increase in duodenal eosinophils in patients with early satiety [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. However, increased duodenal eosinophilia can occur in a healthy population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. It is also unclear if this upregulation in mucosal immunity is due to changes in the upper gut microbiome or diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171654856\">",
"    <span class=\"h2\">",
"     Psychosocial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional dyspepsia may result from of a complex interaction of psychosocial and physiological factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/32\">",
"     32",
"    </a>",
"    ]. Dyspepsia has been associated with generalized anxiety disorder, somatization, and major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/7,33-35\">",
"     7,33-35",
"    </a>",
"    ]. There is also a higher prevalence of functional gastrointestinal disorders in patients with self-reported history of childhood abuse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In a prospective study, depression at baseline was predictive of the new onset of functional dyspepsia at 12-year follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of functional (idiopathic or nonulcer) dyspepsia is made from the characteristic clinical history of postprandial fullness, early satiety, or epigastric",
"    <span class=\"nowrap\">",
"     pain/",
"    </span>",
"    burning for the last three months with symptom onset at least six months before diagnosis",
"    <strong>",
"     and",
"    </strong>",
"    the exclusion of other causes of dyspepsia with upper endoscopy and additional testing, if indicated, based on the symptoms.",
"   </p>",
"   <p>",
"    Gastroesophageal reflux disease can often be confused with functional dyspepsia, as dyspepsia symptoms commonly coexist with heartburn, and some patients with functional dyspepsia respond to PPI. Gastroparesis is rare but can also be confused with functional dyspepsia, as gastric emptying may be slow and symptoms of dyspepsia occur in both disorders; vomiting or weight loss with very slow gastric emptying suggest gastroparesis. The evaluation of a patient with dyspepsia to establish the underlying cause is discussed in detail, separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"     \"Approach to the patient with dyspepsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171654228\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with functional dyspepsia is controversial and alleviates symptoms in only a small proportion of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/39\">",
"     39",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171654397\">",
"    <span class=\"h2\">",
"     Initial approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with functional dyspepsia should be tested and treated for",
"    <em>",
"     H. pylori",
"    </em>",
"    if the local prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is &gt;10 percent (",
"    <a class=\"graphic graphic_table graphicRef87622 \" href=\"mobipreview.htm?9/12/9421\">",
"     table 2",
"    </a>",
"    ). &nbsp; &nbsp;",
"    <br/>",
"    <br/>",
"    Proton pump inhibitors (PPIs) should be considered in patients with functional dyspepsia who test negative for",
"    <em>",
"     H. pylori",
"    </em>",
"    , patients with persistent symptoms after eradication of",
"    <em>",
"     H. pylori,",
"    </em>",
"    or as empiric therapy if the local prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is low (&lt;5 percent) (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"mobipreview.htm?28/19/28988\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H171652745\">",
"     'Helicobacter pylori test and treat'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H86157246\">",
"     'Antisecretory therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Either strategy, to test and treat for",
"    <em>",
"     H. pylori",
"    </em>",
"    or a trial of PPIs, may be considered in areas where the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is intermediate, 5 to 10 percent (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"mobipreview.htm?28/19/28988\">",
"     table 3",
"    </a>",
"    ). The decision should include consideration of the patient's age, past history, comorbidities, symptom duration, risk factors for",
"    <em>",
"     H. pylori",
"    </em>",
"    &nbsp;infection, availability and cost of diagnostic testing, and patient preference.",
"   </p>",
"   <p>",
"    If symptoms do not improve after eight weeks of PPI, a therapeutic trial with a tricyclic antidepressant should be initiated. However, a large number of patients will continue to have symptoms despite this approach and other therapies should be considered in these patients. (See",
"    <a class=\"local\" href=\"#H171652648\">",
"     'Antidepressants'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H86158072\">",
"     'Subsequent approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171652745\">",
"    <span class=\"h3\">",
"     Helicobacter pylori test and treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    eradication is associated with significant benefits in a subset of patients with functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. We therefore recommend screening for",
"    <em>",
"     H. pylori",
"    </em>",
"    , if the local prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is greater than 5 percent",
"    <strong>",
"     and",
"    </strong>",
"    if no biopsies for H. pylori were performed on upper endoscopy as part of the evaluation of dyspepsia (",
"    <a class=\"graphic graphic_table graphicRef87622 \" href=\"mobipreview.htm?9/12/9421\">",
"     table 2",
"    </a>",
"    ). Testing for",
"    <em>",
"     H. pylori",
"    </em>",
"    &nbsp;should be performed with a urea breath test or stool antigen assay. Serologic testing should not be used due to their low positive predictive value. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review of 17 randomized controlled trials included 3566 patients with functional dyspepsia. Eradication of",
"    <em>",
"     H. pylori",
"    </em>",
"    was associated with a small but significant benefit, with treatment of 14 patients needed to cure one case of functional dyspepsia (RRR 10 percent, 95% CI 6-14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In a subsequent randomized control trial, 404 patients with functional dyspepsia and",
"    <em>",
"     H. pylori",
"    </em>",
"    were randomized to treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/41\">",
"     41",
"    </a>",
"    ]. At 12-month follow-up, patients treated with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication therapy were significantly more likely to have symptomatic improvement as compared with controls (49 versus 36 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"     \"Treatment regimens for Helicobacter pylori\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86157246\">",
"    <span class=\"h3\">",
"     Antisecretory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisecretory therapy with once daily proton pump inhibitor should be considered in patients with functional dyspepsia with no evidence of",
"    <em>",
"     H. pylori",
"    </em>",
"    , persistent symptoms after eradication of",
"    <em>",
"     H. pylori,",
"    </em>",
"    or as empiric therapy if the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is very low (&lt;5 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171652325\">",
"    <span class=\"h4\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPIs appear to be moderately effective in the treatment of some patients with functional dyspepsia (",
"    <a class=\"graphic graphic_table graphicRef65374 \" href=\"mobipreview.htm?28/19/28988\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of seven studies that included 3725 patients found that PPIs were significantly more effective than placebo for reducing symptoms (RRR 10 percent, 95% CI 2.7-17.3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/43\">",
"     43",
"    </a>",
"    ]. In a stratified analysis, efficacy was confined to patients with predominant epigastric pain or reflux symptoms, but not in those with predominant postprandial fullness, early satiety, bloating or belching.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171652332\">",
"    <span class=\"h4\">",
"     H2 receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with functional dyspepsia are more likely to respond to H2 receptor antagonists (H2RA) than to placebo. However, the effect of H2RAs in relieving symptoms of functional dyspepsia is likely to be small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 2006 meta-analysis that included twelve trials with a total of 2183 patients, H2RAs were associated with a 23 percent reduction in symptoms compared to placebo (RRR 23 percent, 95% CI 8-35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/45\">",
"     45",
"    </a>",
"    ]. The NNT with H2RAs to improve one case of dyspepsia was seven subjects (95% CI 5-21). However, the quality of most trials included was poor and there was significant heterogeneity among studies. Another limitation of these studies is that patients with GERD may have been misclassified as having functional dyspepsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171652648\">",
"    <span class=\"h3\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central mechanisms may contribute to functional dyspepsia either through increased upper gastrointestinal sensitivity or through other mechanisms. Tricyclic antidepressants should be considered in patients with functional dyspepsia and persistent symptoms despite PPI therapy for to eight weeks.",
"   </p>",
"   <p>",
"    A therapeutic trial should begin with a low dose (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    10 to 25 mg at night or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    25 to 50 mg at night in women only, due to the risk of priapism in men), adjusting the dose upward while observing for daytime sedation or other side effects. We usually advise trying the drug for 8 to 12 weeks before stopping if it is ineffective. If the patient responds in a few weeks, we usually continue the drug for about six months and then try stopping the drug. It can be resumed if dyspepsia recurs. &nbsp; &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    In a randomized control trial, 107 patients with functional dyspepsia refractory to PPI therapy and prokinetics were assigned to low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/41/41624?source=see_link\">",
"     imipramine",
"    </a>",
"    (50 mg daily) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/47\">",
"     47",
"    </a>",
"    ]. Patients treated with imipramine were significantly less likely to have had a treatment failure at 12 weeks as compared with placebo (22 versus 46 percent). However, patients on imipramine were significantly more likely to have withdrawn from the study due to side effects. Low dose tricyclic antidepressant drugs may also improve associated symptoms including insomnia and fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no current evidence to support the use of selective serotonin reuptake inhibitors in patients with functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. The results of a large randomized controlled trial evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25481?source=see_link\">",
"     escitalopram",
"    </a>",
"    may clarify their role in the management of patients with functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86158072\">",
"    <span class=\"h2\">",
"     Subsequent approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few therapeutic options for patients with functional dyspepsia who fail to respond to initial management with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication, empiric PPI, and tricyclic antidepressant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/39\">",
"     39",
"    </a>",
"    ]. Prokinetics can be considered in short courses. Antinociceptive agents can be considered in patients who fail a four-week trial of prokinetic agents or those who cannot tolerate prokinetics. Psychotherapy should be considered for motivated patients who associate symptoms with stressors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86157737\">",
"    <span class=\"h3\">",
"     Prokinetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible relationship between nonulcer dyspepsia and abnormal gastric emptying provided the rationale for treatment trials of prokinetic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/45\">",
"     45",
"    </a>",
"    ]. We limit a trial of prokinetics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (5 to 10 mg three times daily one-half an hour before meals and at night for about four weeks) in patients in whom other therapies have failed. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Although meta-analyses have demonstrated an improvement in functional dyspepsia in patients treated with prokinetics, these results are driven by small positive studies as larger studies were negative. The effect may also reflect publication bias. In addition, several prokinetics are also associated with serious side effects with long-term use and have limited availability.",
"   </p>",
"   <p>",
"    A systematic review focusing on cisapride and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    (neither of which is available by prescription in the United States) identified 17 placebo-controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/52\">",
"     52",
"    </a>",
"    ]. Global improvement in symptoms was observed significantly more often with cisapride (OR 2.9, 95% CI 1.5-5.8) and domperidone (OR 7.0, 95% CI 3.6-16) as compared with placebo. In a meta-analysis that included 19 trials with a total of 3178 patients, prokinetics were associated with a 33 percent reduction in symptoms as compared with placebo (RRR 33 percent, 95% CI 18-45 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/45\">",
"     45",
"    </a>",
"    ]. Domperidone is associated with a risk of QT prolongation and arrhythmias. Domperidone can be obtained from United States compounding pharmacies.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/4/4164?source=see_link\">",
"     Tegaserod",
"    </a>",
"    , a partial 5-HT4 receptor agonist, improves gastric emptying and was superior to placebo in relieving symptoms of functional dyspepsia but has been withdrawn due to cardiovascular side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory activity that has prokinetic effects and probably effects on gastric accommodation and hypersensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, in two phase III multicenter trials, itopride was not significantly better than placebo in relieving symptoms of functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acotiamide is an anticholinesterase drug that may improve gastric motility and gastric accommodation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/57\">",
"     57",
"    </a>",
"    ]. While not commercially available, limited data suggest that acotiamide may improve symptoms in patients with functional dyspepsia. In a phase III randomized controlled trial, 892 patients with functional dyspepsia were randomly assigned to acotiamide or placebo for four weeks. Patients who received acotiamide were more likely to have significant improvement in all three meal-related symptoms (postprandial fullness, upper abdominal bloating, and early satiation; 15 versus 9 percent) and a higher overall treatment response as compared with placebo (52 versus 35 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/58\">",
"     58",
"    </a>",
"    ]. During the four-week post-treatment follow-up period, improvement in meal related symptoms was sustained in patients treated with acotiamide as compared with placebo. However, additional long-term trials are needed to confirm these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H437005692\">",
"    <span class=\"h3\">",
"     Fundic relaxant drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence that relaxing the gastric fundus may improve early satiation and postprandial fullness. In a small randomized trial, as compared with placebo,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"     buspirone",
"    </a>",
"    (10 mg, three times daily for four weeks) increased gastric accommodation and reduced the overall severity of symptoms of dyspepsia, despite slowing gastric emptying of liquids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6114964\">",
"    <span class=\"h3\">",
"     Antinociceptive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is hypothesized that antinociceptive agents may impact the central processing of pain, thereby decreasing visceral hypersensitivity that has been associated with functional dyspepsia.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     Carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    can be considered in patients who fail a four-week trial of prokinetic agents and in patients who cannot tolerate prokinetics. &nbsp;",
"   </p>",
"   <p>",
"    However, it is important to recognize there are no successful trials of anti-nociceptives in patients with functional dyspepsia and evidence to support their use in patients with functional dyspepsia is indirect. As an example, a post hoc analysis of data obtained from six RCTs in patients with generalized anxiety disorder and prominent gastrointestinal symptoms showed that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    was significantly more effective than placebo in treating both anxiety and gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171655125\">",
"    <span class=\"h3\">",
"     Psychological therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychological therapy (cognitive behavioral therapy, hypnotherapy, or psychotherapy) has benefited selected patients and should be considered for motivated patients who associate symptoms with stressors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=see_link&amp;anchor=H432862147#H432862147\">",
"     \"Overview of psychotherapies\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Complementary and alternative medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complementary and alternative medicine approaches to functional dyspepsia have been described. However, further studies are needed before they can be recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of several low quality studies involving herbal and natural products, acupuncture, and homeopathy suggested a benefit from peppermint oil and STW5, a European multiherbal preparation that includes peppermint and caraway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/67\">",
"     67",
"    </a>",
"    ]. STW5 may improve symptoms of functional dyspepsia by stimulating gastric fundic relaxation and antral motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/5\">",
"     5",
"    </a>",
"    ]. A subsequent eight-week placebo-controlled trial also found symptomatic improvement in patients treated with STW5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H171654535\">",
"    <span class=\"h3\">",
"     Dietary modification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although lipid and possibly other food substances instilled into the duodenum can induce dyspepsia due to changes in gastric motility, there are limited data to support dietary modification in patients with functional dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A population case&ndash;control study failed to find an association between various culprit foods and functional gastrointestinal disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35272/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=see_link\">",
"       \"Patient information: Stomach ache and stomach upset (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/24/5506?source=see_link\">",
"       \"Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional dyspepsia is defined as the presence of one or more of the following: postprandial fullness, early satiation, epigastric pain or burning, and no evidence of structural disease (including at upper endoscopy) to explain the symptoms. While patients with these symptoms and a negative diagnostic evaluation likely have functional dyspepsia, according to the Rome III guidelines, the criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of functional dyspepsia is made by the exclusion of other causes of dyspepsia with an upper endoscopy and additional testing, as indicated, based on the symptoms. The evaluation of a patient with dyspepsia to establish the underlying cause is discussed in detail, separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=see_link\">",
"       \"Approach to the patient with dyspepsia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of patients with functional dyspepsia is controversial and alleviates symptoms in only a small proportion of patients. (See",
"      <a class=\"local\" href=\"#H171654228\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An assessment of",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      (",
"      <em>",
"       H. pylori",
"      </em>",
"      ) should be performed if the local prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      is &gt;5 percent and if gastric biopsies were not obtained for",
"      <em>",
"       H. pylori",
"      </em>",
"      on upper endoscopy for evaluation for dyspepsia (",
"      <a class=\"graphic graphic_table graphicRef87622 \" href=\"mobipreview.htm?9/12/9421\">",
"       table 2",
"      </a>",
"      ). We suggest treatment for",
"      <em>",
"       H. pylori",
"      </em>",
"      in patients with functional dyspepsia who test positive for an infection (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=see_link\">",
"       \"Treatment regimens for Helicobacter pylori\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest a four- to eight-week trial of a once daily proton pump inhibitor in patients with functional dyspepsia and no evidence of",
"      <em>",
"       H. pylori",
"      </em>",
"      , patients with persistent symptoms after eradication of",
"      <em>",
"       H. pylori,",
"      </em>",
"      or as empiric therapy if the prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      is low (&lt;5 percent) (",
"      <a class=\"graphic graphic_table graphicRef87622 \" href=\"mobipreview.htm?9/12/9421\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65374 \" href=\"mobipreview.htm?28/19/28988\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest a tricyclic antidepressant drug for patients with persistent symptoms after an eight-week trial of a proton pump inhibitor, especially in patients with insomnia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We start with a low dose (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      10 mg at bedtime,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/14/39144?source=see_link\">",
"       desipramine",
"      </a>",
"      25 mg at bedtime, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/0/24584?source=see_link\">",
"       trazodone",
"      </a>",
"      25 mg at bedtime) and increasing after a few days, usually to only two or three times these doses. (See",
"      <a class=\"local\" href=\"#H171652648\">",
"       'Antidepressants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the use of prokinetics in patients in whom eradication of",
"      <em>",
"       H. pylori",
"      </em>",
"      and a trial of proton pump inhibitor and tricyclic antidepressant has failed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In such patients, we generally limit a trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      to 5 to 10 mg three times daily one-half an hour before meals and at night for about four weeks. The risk of side effects, including tardive dyskinesia, increase with the cumulative dose and duration of treatment. (See",
"      <a class=\"local\" href=\"#H86157737\">",
"       'Prokinetic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who fail a four-week trial of prokinetic agents or in patients who cannot tolerate prokinetics, treatment options include antinociceptive agents and psychological therapy. (See",
"      <a class=\"local\" href=\"#H171655125\">",
"       'Psychological therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several dietary, complementary, and alternative medicine approaches to functional dyspepsia have been described. However, further studies are needed before these approaches can be routinely recommended. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complementary and alternative medicine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H171654535\">",
"       'Dietary modification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/1\">",
"      Talley NJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/2\">",
"      Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/3\">",
"      Thumshirn M. Pathophysiology of functional dyspepsia. Gut 2002; 51 Suppl 1:i63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/4\">",
"      Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/5\">",
"      Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/6\">",
"      Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006; 130:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/7\">",
"      Scolapio JS, Camilleri M. Nonulcer dyspepsia. Gastroenterologist 1996; 4:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/8\">",
"      Koch KL, Stern RM. Functional disorders of the stomach. Semin Gastrointest Dis 1996; 7:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/9\">",
"      Quartero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/10\">",
"      Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/11\">",
"      Mearin F, Cucala M, Azpiroz F, Malagelada JR. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/12\">",
"      Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/13\">",
"      Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/14\">",
"      Camilleri M, Malagelada JR, Kao PC, Zinsmeister AR. Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986; 31:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/15\">",
"      Iovino P, Azpiroz F, Domingo E, Malagelada JR. The sympathetic nervous system modulates perception and reflex responses to gut distention in humans. Gastroenterology 1995; 108:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/16\">",
"      Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and (anticipated) gastric distension in functional dyspepsia and the role of anxiety: a H(2)(15)O-PET study. Am J Gastroenterol 2010; 105:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/17\">",
"      Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/18\">",
"      Berc&iacute;k P, De Giorgio R, Blennerhassett P, et al. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 2002; 123:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/19\">",
"      Minocha A, Mokshagundam S, Gallo SH, Rahal PS. Alterations in upper gastrointestinal motility in Helicobacter pylori-positive nonulcer dyspepsia. Am J Gastroenterol 1994; 89:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/20\">",
"      Mearin F, de Ribot X, Balboa A, et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995; 37:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/21\">",
"      Tack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/22\">",
"      Mearin F, P&eacute;rez-Oliveras M, Perell&oacute; A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/23\">",
"      Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010; 138:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/24\">",
"      Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on \"Helicobacter pylori eradication in functional dyspepsia\". Arch Intern Med 2011; 171:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/25\">",
"      Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007; 5:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/26\">",
"      Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/27\">",
"      Moayyedi P. Dyspepsia. Curr Opin Gastroenterol 2012; 28:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/28\">",
"      Futagami S, Shindo T, Kawagoe T, et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol 2010; 105:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/29\">",
"      Walker MM, Talley NJ. Clinical value of duodenal biopsies--beyond the diagnosis of coeliac disease. Pathol Res Pract 2011; 207:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/30\">",
"      Kato M, Kephart GM, Talley NJ, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998; 252:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/31\">",
"      DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol 2006; 9:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/32\">",
"      Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999; 45 Suppl 2:II25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/33\">",
"      Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/34\">",
"      Goodwin RD, Cowles RA, Galea S, Jacobi F. Gastritis and mental disorders. J Psychiatr Res 2013; 47:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/35\">",
"      Mak AD, Wu JC, Chan Y, et al. Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study. Aliment Pharmacol Ther 2012; 36:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/36\">",
"      Drossman DA, Talley NJ, Leserman J, et al. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995; 123:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/37\">",
"      Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/38\">",
"      Koloski NA, Jones M, Kalantar J, et al. The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/39\">",
"      Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/40\">",
"      Moayyedi P, Deeks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98:2621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/41\">",
"      Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/42\">",
"      Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/43\">",
"      Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/44\">",
"      Moayyedi P, Delaney BC, Vakil N, et al. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/45\">",
"      Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; :CD001960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/46\">",
"      Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/47\">",
"      Wu JC, Cheong PK, Chan YC, et al. A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia (FD) (abstract #216). Gastroenterology 2011; 140:S50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/48\">",
"      Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/49\">",
"      Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/50\">",
"      van Kerkhoven LA, Laheij RJ, Aparicio N, et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008; 6:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/51\">",
"      Talley NJ, Locke GR 3rd, Herrick LM, et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012; 33:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/52\">",
"      Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/53\">",
"      Vakil N, Laine L, Talley NJ, et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008; 103:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/54\">",
"      Iwanaga Y, Miyashita N, Saito T, et al. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Jpn J Pharmacol 1996; 71:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/55\">",
"      Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/56\">",
"      Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008; 57:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/57\">",
"      Seto K, Sasaki T, Katsunuma K, et al. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil 2008; 20:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/58\">",
"      Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012; 61:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/59\">",
"      Bytzer P. New hope for functional dyspepsia? Gut 2012; 61:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/60\">",
"      Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/61\">",
"      Stein DJ, Bruce Lydiard R, Herman BK, Mandel FS. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009; 24:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/62\">",
"      Hamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/63\">",
"      Mine K, Kanazawa F, Hosoi M, et al. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions. Dig Dis Sci 1998; 43:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/64\">",
"      Jones MP, Maganti K. Symptoms, gastric function, and psychosocial factors in functional dyspepsia. J Clin Gastroenterol 2004; 38:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/65\">",
"      Calvert EL, Houghton LA, Cooper P, et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/66\">",
"      Zeng F, Qin W, Ma T, et al. Influence of acupuncture treatment on cerebral activity in functional dyspepsia patients and its relationship with efficacy. Am J Gastroenterol 2012; 107:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/67\">",
"      Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004; 2:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/68\">",
"      von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/69\">",
"      Barbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995; 40:1636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/70\">",
"      Feinle C, Meier O, Otto B, et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35272/abstract/71\">",
"      Saito YA, Locke GR 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100:2743.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 19 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35272=[""].join("\n");
var outline_f34_28_35272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gastric motility and compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Visceral hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Altered gut microbiome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H171654856\">",
"      Psychosocial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H171654228\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H171654397\">",
"      Initial approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171652745\">",
"      - Helicobacter pylori test and treat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86157246\">",
"      - Antisecretory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H171652325\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H171652332\">",
"      H2 receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171652648\">",
"      - Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86158072\">",
"      Subsequent approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86157737\">",
"      - Prokinetic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H437005692\">",
"      - Fundic relaxant drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6114964\">",
"      - Antinociceptive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171655125\">",
"      - Psychological therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Complementary and alternative medicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H171654535\">",
"      - Dietary modification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/19\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/19|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37532\" title=\"table 1\">",
"      Diagnostic criteria for functional dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/12/9421\" title=\"table 2\">",
"      Helicobacter pylori infection globally",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/19/28988\" title=\"table 3\">",
"      PPI recommended doses",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/4/27720?source=related_link\">",
"      Approach to the patient with dyspepsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/12/43209?source=related_link\">",
"      Etiology and diagnosis of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/24/5506?source=related_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23049?source=related_link\">",
"      Treatment regimens for Helicobacter pylori",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35273="Anatomy SC IJ central line";
var content_f34_28_35273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F74801%7EEM%2F79232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F74801%7EEM%2F79232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Anatomy of the subclavian and internal jugular veins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External landmarks for the central venous catheter placement in the internal jugular vein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35273=[""].join("\n");
var outline_f34_28_35273=null;
var title_f34_28_35274="Post-cardiac arrest management in adults";
var content_f34_28_35274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-cardiac arrest management in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Jon C Rittenberger, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Clifton W Callaway, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Ron M Walls, MD, FRCPC, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/28/35274/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/28/35274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9724120\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrest results in over 300,000 deaths per year in North America alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/1\">",
"     1",
"    </a>",
"    ]. However, advances in cardiopulmonary resuscitation and post-cardiac arrest care have improved outcomes in select cohorts of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Among these advances are the use of therapeutic hypothermia and other interventions to improve the care of patients following cardiac arrest.",
"   </p>",
"   <p>",
"    The critical interventions in post-cardiac arrest management will be reviewed here. Basic and advanced life support for adult victims of cardiac arrest and long-term care for survivors of cardiac arrest are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7082819\">",
"    <span class=\"h1\">",
"     MAJOR PROBLEMS AND GOALS OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of the post-cardiac arrest patient is complex and must address multiple major problems simultaneously. Issues to be addressed include: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determining and treating the cause of cardiac arrest",
"     </li>",
"     <li>",
"      Minimizing brain injury",
"     </li>",
"     <li>",
"      Managing cardiovascular dysfunction",
"     </li>",
"     <li>",
"      Managing problems that may arise from global ischemia and reperfusion injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immediately following resuscitation from cardiac arrest, the patient can develop a number of problems due to medical comorbidities and the sequelae of ischemic injury sustained during the arrest. The most immediate threat to survival during the first minutes to hours is cardiovascular collapse. Interventions to optimize blood pressure and maintain end-organ perfusion (eg, boluses of IV fluid, vasopressors, and inotropes) can help prevent secondary injury from hypotension. Additional short-term goals during the first six hours of care include optimizing oxygenation and ventilation and correcting electrolyte abnormalities. Determination of the etiology of cardiac arrest and the initiation of relevant treatments are performed concurrently with resuscitation efforts in order to prevent recurrent arrest and optimize outcome. Evidence supports the use of therapeutic hypothermia to minimize brain injury and target body temperatures should be achieved within the first few hours following resuscitation. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724127\">",
"    <span class=\"h1\">",
"     DETERMINING THE CAUSE AND EXTENT OF INJURY AFTER CARDIAC ARREST",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases of sudden cardiac arrest (SCA), the etiology determines therapy. A focused history and physical examination are performed and diagnostic studies obtained in order to identify possible causes for the arrest and ongoing or imminent threats to life. Cardiovascular disease is the most common cause of SCA, but a broad differential diagnosis should be considered. Common etiologies for SCA are described in the attached tables (",
"    <a class=\"graphic graphic_table graphicRef70060 \" href=\"mobipreview.htm?10/45/10972\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52416 \" href=\"mobipreview.htm?17/18/17708\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac arrest sustained during trauma has different causes than nontraumatic arrest (assuming cardiac arrest did not precede and thereby cause the trauma) and is managed differently. Issues related to trauma management are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=see_link\">",
"     \"Initial evaluation and management of shock in adult trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368249\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients are comatose after resuscitation from SCA and cannot provide a history of present illness or preexisting conditions. Therefore, clinicians should speak with anyone who can provide insight into the history (eg, family, friends, witnesses, emergency medical services personnel) to help determine the etiology of sudden cardiac arrest (SCA) as rapidly as possible after the return of spontaneous circulation (ROSC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H919559\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination begins with an assessment of the airway, breathing, and circulation (ABC&rsquo;s). Airway patency and security are evaluated first. A dislodged endotracheal tube or tracheostomy tube will rapidly lead to recurrent cardiac arrest. (See",
"    <a class=\"local\" href=\"#H43368342\">",
"     'Initial interventions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Once the airway is secure, ventilation is assessed. Listen for abnormal lung sounds (eg, asymmetry, wheezing, crackles), which suggest a pulmonary or cardiac problem, or possibly a malpositioned endotracheal tube.",
"   </p>",
"   <p>",
"    Next, circulation and end-organ perfusion are evaluated. Pulse rate and character (eg, full, thready), blood pressure, and skin appearance (eg, pink, mottled, cool) provide clues to the adequacy of perfusion. A loud or harsh cardiac murmur or rub suggests a cardiac etiology. Tachycardia is expected immediately after ROSC; bradycardia suggests an abnormal cardiac response, hypoxia, or severe metabolic disturbance (eg, electrolyte abnormality).",
"   </p>",
"   <p>",
"    A rigid abdomen suggests a surgical emergency or may be due to an air-filled stomach. Significant quantities of blood in the rectum or nasogastric tube suggest a hemorrhagic cause (eg, gastrointestinal bleeding). Extremity signs of deep venous thrombosis (eg, unilateral leg edema), IV drug abuse, or a source of sepsis may suggest a diagnosis. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368755\">",
"    <span class=\"h2\">",
"     Baseline neurologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A baseline neurologic examination should be performed to help determine the possible cause, likely clinical course, and need for neurological interventions (eg, therapeutic hypothermia). Temporary avoidance or cessation of neuromuscular blockade and sedation is necessary for a valid examination. The examination may be delayed if long-acting drugs have been administered. Train-of-four testing can be used to determine the degree of neuromuscular blockade. Train-of-four testing and the neurologic examination in the patient with depressed mental status are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of neuromuscular blocking medications in critically ill patients\", section on 'Administration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link&amp;anchor=H5#H5\">",
"     \"Stupor and coma in adults\", section on 'Neurologic examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asymmetric neurologic findings are not expected following ROSC and suggest a structural intracranial lesion. Brainstem responses, including the pupillary, corneal, gag, and cough response to stimulation, correlate with survival and should be assessed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/7\">",
"     7",
"    </a>",
"    ]. The Glasgow Coma Score should be determined, with particular attention paid to the motor score, which correlates closely with neurologic outcome. Patients who cannot perform purposeful movements or follow basic commands generally need treatment with induced hypothermia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368801\">",
"    <span class=\"h2\">",
"     Diagnostic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic tests, including an electrocardiogram, imaging studies, and laboratory tests, are usually required to determine the etiology of cardiac arrest, to confirm endotracheal tube positioning and assess for chest trauma from CPR, and to ascertain the involvement of specific organ systems and gauge the severity of injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70225156\">",
"    <span class=\"h3\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myocardial infarction, cardiomyopathy, and primary arrhythmia are the most common causes for cardiac arrest. Following ROSC, a 12-lead electrocardiogram (ECG) should be rapidly obtained and evaluated for signs of ST-elevation myocardial infarction (STEMI) (including a new left bundle branch block) that requires emergent reperfusion therapy. Abnormalities of conduction intervals, electrical axis, and T-waves may provide clues to the etiology. As an example, a prolonged QTc interval may reflect a primary arrhythmia, accidental hypothermia, or an electrolyte abnormality. Evidence of right heart strain (eg, right axis deviation) may be present in the setting of pulmonary embolus.",
"   </p>",
"   <p>",
"    Among patients with out-of-hospital cardiac arrest (OHCA), significant coronary artery disease is often present in the absence of an acute STEMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The incidence of coronary artery lesions is highest among patients whose presenting arrhythmia is ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. Thus, emergent cardiac catheterization may be needed in patients without a STEMI but who have a concerning story (antecedent chest pain or shortness of breath and cardiac risk factors) or whose presenting arrhythmia was VF or pulseless VT. (See",
"    <a class=\"local\" href=\"#H43368525\">",
"     'Coronary revascularization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When the diagnosis of acute coronary syndrome (ACS) is uncertain based on ECG findings, bedside echocardiography may demonstrate focal wall motion abnormalities, suggesting acute myocardial infarction. Global but not focal hypokinesis is expected following cardiac arrest. (See",
"    <a class=\"local\" href=\"#H9724141\">",
"     'Imaging studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Ongoing cardiogenic shock may be the sole manifestation of ACS in some patients with ROSC. Such patients may benefit from reperfusion established via cardiac catheterization or from placement of an intra-aortic balloon pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724141\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtain chest radiography to evaluate for pulmonary pathology and to confirm proper positioning of the endotracheal tube and central venous catheter. Pulmonary edema and evidence of aspiration are common findings after cardiopulmonary resuscitation, but may be unrelated to the cause of arrest. Pneumothorax or mediastinal abnormalities suggestive of aortic dissection represent ongoing threats to patient survival and require immediate intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Chest radiograph'",
"    </a>",
"    .) Enlarged aorta or concerning mediastinal findings on chest x-ray should prompt CT scan imaging.",
"   </p>",
"   <p>",
"    Bedside emergency ultrasound can help to identify causes of arrest that represent ongoing threats to life, including pericardial tamponade, pneumothorax, catastrophic pulmonary embolism (PE), and intraperitoneal bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. Ultrasound can be used to assess right ventricular size and function (which may be abnormal with PE), determine inferior vena cava diameter (which may be abnormal with hypovolemia), and assess global cardiac function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4490?source=see_link&amp;anchor=H13#H13\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unenhanced computerized tomography (CT) of the brain can detect early cerebral edema or intracranial hemorrhage in the comatose post-cardiac arrest patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Approximately 4 percent of patients in one series exhibited intracranial hemorrhage that was considered to be the cause of their arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/16\">",
"     16",
"    </a>",
"    ], altering both expected prognosis and precluding the use of anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=see_link\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT of the chest is useful in cases of suspected pulmonary embolism (PE). However, CT may be delayed if there is concern for acute renal injury. In this setting, if the clinician strongly suspects that a massive PE accounts for the patient&rsquo;s arrest, other imaging studies (eg, transthoracic or transesophageal echocardiography, ultrasonography of the lower extremities) can be performed while treatment with empiric anticoagulation is started. The high incidence of abnormalities on chest x-ray limits the utility of",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    scanning in this population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a markedly elevated lactate (&gt;15",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    traumatic mechanism, or clinical findings of peritonitis, CT imaging of the abdomen and pelvis is useful for determining an intra-abdominal cause of arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H919578\">",
"    <span class=\"h3\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing may provide insight into the cause of arrest, but is also necessary to evaluate the extent and progression of arrest-related injury to organ systems. In particular, electrolyte and acid-base disturbances require close monitoring during resuscitation and on-going management.",
"   </p>",
"   <p>",
"    Following ROSC, we suggest the following approach to laboratory testing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arterial blood gas measurements are obtained every six hours during therapeutic hypothermia and rewarming to assess acid-base status and are used to guide ventilator management. Arterial vascular access is obtained routinely in comatose post-cardiac arrest patients given the need for frequent arterial blood gas measurements and the common use of vasopressor and inotropic drugs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15894?source=see_link\">",
"       \"Arterial blood gases\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"       \"Simple and mixed acid-base disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Basic serum electrolyte concentrations, including sodium, potassium, chloride, and bicarbonate, are obtained every six hours during therapeutic hypothermia and rewarming to detect abnormalities. Rapid fluctuations in serum potassium may occur as a result of ischemia, acidosis, and catecholamine administration. Both high and low potassium can cause arrhythmias and must be treated immediately. Note that hypokalemia is often accompanied by hypomagnesaemia, which should also be corrected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=see_link\">",
"       \"Treatment and prevention of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=see_link\">",
"       \"Clinical manifestations and treatment of hypokalemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood counts are measured to detect anemia and other hematologic abnormalities. Profound anemia suggests blood loss as a factor contributing to cardiac arrest. Leukocytosis of 10,000 to 20,000 is common and may represent acute demargination of white blood cells and inflammation. Markedly elevated leukocytosis should prompt investigation of a cause other than cardiac arrest.",
"     </li>",
"     <li>",
"      Serum troponin is measured every 8 to 12 hours for 24 hours to detect myocardial injury. If initial measurements are elevated, testing continues until there is clear evidence they are decreasing. Cardiac arrest, CPR, and defibrillation often cause mild increases in the serum troponin (troponin I 0 to 5",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      but rising or higher levels suggest acute coronary artery occlusion. Using biomarkers to diagnose myocardial infarction in patients with renal injury is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=see_link\">",
"       \"Serum cardiac enzymes in patients with renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum lactate concentration is measured every six hours during therapeutic hypothermia and rewarming. Initial lactate concentrations and the rate of lactate clearance correlate with survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/21\">",
"       21",
"      </a>",
"      ]. Lactic acidosis, with serum lactate concentrations up to approximately 15",
"      <span class=\"nowrap\">",
"       mmol/L,",
"      </span>",
"      is common after cardiac arrest, but higher levels suggest ongoing intra-abdominal or muscle compartment ischemia. Lactate should clear over time after adequate perfusion is restored.",
"     </li>",
"     <li>",
"      Specific toxicology studies may be obtained in patients with a history of drug ingestion, signs of a toxicologic syndrome (eg, sympathomimetic poisoning), or clinical suspicion of poisoning. As examples, myocardial infarction or arrhythmia may be caused by acute cocaine or methamphetamine intoxication, cardiopulmonary collapse may be precipitated by massive antidepressant overdose, and sedative overdose may contribute to and prolong coma independent of any brain injury sustained during a cardiac arrest. The presence of long-acting opioids (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ) may prompt use of a reversal agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      ) before neurological testing. Evaluation and management of the unresponsive and critically-ill poisoned patient is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43047?source=see_link\">",
"       \"Initial management of the critically ill adult with an unknown overdose\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ischemia can impair kidney and liver function, which may affect drug dosing and decisions to use intravenous contrast. Thus, we recommend initial measurements of renal and hepatic function. Most patients require central venous access, arterial access, and potentially other invasive procedures. Therefore, we recommend assessment of PT, aPTT, and INR along with initial laboratory testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724162\">",
"    <span class=\"h1\">",
"     RESPIRATORY CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368342\">",
"    <span class=\"h2\">",
"     Initial interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must first ensure a patent and functioning airway. An obstructed airway can rapidly lead to recurrent cardiac arrest. If a temporizing rescue airway device (eg, laryngeal mask, laryngeal tube) was used during resuscitation, this is replaced with a definitive airway at the earliest opportunity. Stomach decompression with a gastric tube is indicated.",
"   </p>",
"   <p>",
"    The details of airway management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link\">",
"     \"Basic airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733416\">",
"    <span class=\"h2\">",
"     Mechanical ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following guidelines for mechanical ventilation in the post-cardiac arrest patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintain the carbon dioxide tension (PaCO2) no lower than 40 to 45 mmHg (or end-tidal CO2 35 to 40 mmHg).",
"      <br/>",
"      <br/>",
"      Targeting this slightly higher PaCO2 range prevents hypocapnia-induced cerebral vasoconstriction and partly accounts for the temperature correction when induced hypothermia is used.",
"     </li>",
"     <li>",
"      Maintain oxygen saturation (SpO2) &gt;94 percent. Avoid prolonged hyperoxia (PaO2 &gt;300 mmHg), which has been associated with worse outcome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management of mechanical ventilation in the post-cardiac arrest patient must balance the need to reverse hypoxia and acidosis with the potential deleterious effects of hyperventilation and hyperoxia. Specifically, routine hyperventilation should not be used to compensate for metabolic acidosis. The modes and management of mechanical ventilation are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link\">",
"     \"Overview of mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6554?source=see_link\">",
"     \"Mechanical ventilation of adults in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebrovascular responses to PaCO2 persist after cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and hyperventilation causes cerebral vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Therefore, ventilation should be titrated to keep the PaCO2 no lower than 40 to 45 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/4,26\">",
"     4,26",
"    </a>",
"    ]. It is unknown if higher PaCO2 levels contribute to vasodilation, hyperemia, or cerebral edema. Hyperventilation can also decrease preload, resulting in reduced cardiac output and coronary perfusion pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypoxia must be avoided in the post-cardiac arrest patient, but hyperoxia may also be harmful. We suggest titrating the fraction of inspired oxygen (FiO2) to the lowest value necessary to maintain oxygen saturation (SpO2) at 94 to 99 percent, or the PaO2 to around 100 mmHg.",
"   </p>",
"   <p>",
"    This approach is supported by several retrospective studies. In one cohort of 6326 post-cardiac arrest patients, the odds ratio for death among patients with hyperoxia (defined as PaO2 &gt;300 mmHg on the first arterial blood gas) was 1.8 (95% CI 1.5-2.2) compared to patients without hyperoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/28\">",
"     28",
"    </a>",
"    ]. A single center study of 170 patients reported that a higher peak PaO2 during the first 24 hours was associated with increased mortality (OR 1.44; 95% Cl 1.03&ndash;2.02) and poor neurological status at hospital discharge (OR 1.49; 95% CI 1.03&ndash;2.14) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies support the importance of avoiding hyperoxia and the optimal oxygen level in the post-arrest patient remains an area of debate. A retrospective cohort study of 12,108 post-cardiac arrest patients evaluated the worst arterial blood gas obtained during the first 24 hours following resuscitation and found no difference in mortality between the hyperoxia (PaO2 &gt;300 mmHg) and normoxia (PaO2 &lt;300 and &gt;60 mmHg) groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, a randomized trial of 28 patients with out-of-hospital cardiac arrest found no difference in survival to hospital discharge among patients randomly assigned to a goal FiO2 of 30 percent or 100 percent during the first hour of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3956184\">",
"    <span class=\"h2\">",
"     Ensuring adequate oxygen delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapolating from research on sepsis, some researchers advocate maintaining a central venous oxygen saturation (ScvO2) of &ge;70 percent in post-cardiac arrest patients, but whether this goal is optimal remains unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/32\">",
"     32",
"    </a>",
"    ]. Given that the post-arrest syndrome can be similar to that of sepsis, our practice is to maintain ScvO2 of &ge;70 percent and a hematocrit of 30 percent in patients with a presumed cardiac etiology for their arrest. This approach is similar to that of early-goal-directed therapy for sepsis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H3#H3\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Early management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not advocate transfusion to a normal hematocrit given the prothrombotic state seen in post-arrest patients. Failure of the serum lactate to clear over time suggests inadequate perfusion, and prompts us to reevaluate all aspects of oxygen delivery: cardiac output, intravascular volume, hemoglobin concentration, and blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733382\">",
"    <span class=\"h2\">",
"     Interpreting blood gas values during therapeutic hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When therapeutic hypothermia is used, arterial blood gas values can be interpreted with or without correction for the patient&rsquo;s temperature. When a patient&rsquo;s core temperature is 33&ordm;C, the patient&rsquo;s actual PaCO2 may be 6 to 7 mmHg lower than the value reported by the blood gas machine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/33\">",
"     33",
"    </a>",
"    ]. However, there is no evidence to determine whether it is better to use corrected (pH-stat) or uncorrected (alpha-stat) values to adjust ventilation. It is prudent to target slightly higher PaCO2 values in order to avoid accidental hyperventilation and the resulting cerebral vasoconstriction.",
"   </p>",
"   <p>",
"    Note that the metabolic rate of the patient, and thus minute ventilation requirements, decrease as body temperature falls. A blood gas should be obtained after any major change in patient temperature (eg, when a patient treated with hypothermia reaches 33&ordm;C). (See",
"    <a class=\"local\" href=\"#H9724176\">",
"     'Therapeutic (Induced) hypothermia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The interpretation of arterial blood gas results is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=see_link\">",
"     \"Simple and mixed acid-base disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=see_link\">",
"     \"Oxygenation and mechanisms of hypoxemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368503\">",
"    <span class=\"h1\">",
"     HEMODYNAMIC CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368511\">",
"    <span class=\"h2\">",
"     Maintaining end-organ perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;An adequate blood pressure must be maintained in the post-cardiac arrest patient. Episodes of hypotension can cause secondary injury, in addition to any initial insult incurred during the arrest by the brain and other organs. Mean arterial blood pressure (MAP) should be above 65 mmHg to reverse the acute shock state, and preferably 80 to 100 mmHg to optimize cerebral perfusion.",
"   </p>",
"   <p>",
"    When determining blood pressure goals, clinicians must balance the metabolic needs of an ischemic brain with the potential for overstressing a decompensated heart. Cerebral autoregulation is often impaired after cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and brain perfusion declines when the MAP falls below 80 to 100 mmHg. However, if the MAP is adequate, regional cerebral perfusion matches metabolic activity, according to positron emission tomography (PET) studies in post-cardiac arrest patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Thus, maintaining an adequate MAP helps to avoid further brain injury. Maintaining central venous pressures between 8 to 12 mmHg and adequate urine output (&gt;0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour) are additional perfusion goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/32,38\">",
"     32,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Volume replacement, with isotonic saline or lactated ringers, is used to maintain a goal central venous pressure (CVP) of 8 to 12 mmHg. Lactated ringers may avoid hyperchloremic metabolic acidosis in patients requiring large volume infusions during initial resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=see_link&amp;anchor=H1058523188#H1058523188\">",
"     \"Intraoperative fluid management\", section on 'Fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypotonic fluids, which can exacerbate cerebral edema, should be avoided. Rapid infusion (infusion at maximal rate using a pressure bag) of 20 to 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic saline or other crystalloid at 4&deg;C is commonly used to induce hypothermia. Once an adequate CVP has been established, patients whose MAP remains below 80 mmHg generally need treatment with an inotropic agent or vasopressor. Prior to CVP monitoring, it is reasonable to start vasoactive drugs in patients with hypotension that does not resolve after a rapid infusion of 2 liters of isotonic crystalloid.",
"   </p>",
"   <p>",
"    Inotropic and vasopressor support can mitigate the myocardial dysfunction that is common during the first 24 to 48 hours after cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/20,39\">",
"     20,39",
"    </a>",
"    ]. There is no evidence demonstrating the superiority of any one vasopressor in the post-cardiac arrest patient. Commonly employed vasopressors include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"     dopamine",
"    </a>",
"    (5 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"     norepinephrine",
"    </a>",
"    (0.01 to 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute; 0.5 to 70",
"    <span class=\"nowrap\">",
"     mcg/minute),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (0.01 to 1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute; 0.5 to 70",
"    <span class=\"nowrap\">",
"     mcg/minute).",
"    </span>",
"    Studies in septic patients report no difference in mortality between patients treated with dopamine or norepinephrine, but the risk of cardiac arrhythmia may be higher in patients treated with dopamine. Given these data, we use norepinephrine as the first line vasopressor in the undifferentiated post-arrest patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In cases of cardiogenic shock (eg, global hypokinesis on echocardiogram or persistently low SvO2 despite normalized hemoglobin and MAP), inotropic support using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    (2 to 15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"     milrinone",
"    </a>",
"    (loading dose: 50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    over 10 minutes, then 0.375 to 0.75",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute) may be helpful. Either agent may cause hypotension from vasodilation; dobutamine may cause tachyarrhythmias.",
"   </p>",
"   <p>",
"    Inotropic and vasopressor agents require titration over the first 12 to 24 hours following cardiac arrest. Thus, an arterial line for continuous blood pressure monitoring is necessary in the majority of patients. In patients with ongoing cardiovascular shock despite inotropic and vasopressor support, an intra-aortic balloon pulp may be advised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368518\">",
"    <span class=\"h2\">",
"     Preventing arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiarrhythmic drugs should be reserved for patients with recurrent or ongoing unstable arrhythmias. No data support the routine or prophylactic use of antiarrhythmic drugs after the return of spontaneous circulation following cardiac arrest, even if such medications were employed during the resuscitation. Determining and correcting the underlying cause of the arrhythmia (eg, electrolyte disturbance, acute myocardial ischemia, toxin ingestion) is the best intervention. (See",
"    <a class=\"local\" href=\"#H9724127\">",
"     'Determining the cause and extent of injury after cardiac arrest'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43368525\">",
"    <span class=\"h2\">",
"     Coronary revascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent coronary catheterization or reperfusion therapy is indicated for patients with findings on the electrocardiogram (ECG) of ST segment elevation myocardial infarction (STEMI) or new left bundle branch block (LBBB). Some facilities perform coronary catheterization for all patients with return of spontaneous circulation following out-of-hospital cardiac arrest from ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT), regardless of ECG findings, because of the high incidence of coronary artery blockages in this group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8\">",
"     8",
"    </a>",
"    ]. We believe this approach is reasonable; however, it may not be feasible in all institutions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4490?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Coronary angiography'",
"    </a>",
"    .) The contraindications to thrombolytic therapy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=see_link&amp;anchor=H25#H25\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 435 patients, over 70 percent with",
"    <span class=\"nowrap\">",
"     VF/VT",
"    </span>",
"    had significant lesions at catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/9\">",
"     9",
"    </a>",
"    ]. Adjusting for other factors, cardiac arrest patients treated with coronary catheterization were twice as likely to be discharged to home or to acute rehabilitation than patients not so treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Even without coronary revascularization, medical treatments for acute coronary syndrome (eg, antiplatelet and anticoagulation therapy) may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of ECG findings, emergent coronary catheterization may be needed for patients with ongoing hemodynamic instability, which may be due to cardiogenic shock or associated with rising troponin levels, or evidence of focal wall-motion abnormalities on echocardiogram. Thus, we recommend coronary artery catheterization in the post-arrest patient, with precise timing determined by the initial ECG, trajectory of cardiac biomarker levels, presence of shock, and competing needs of ongoing resuscitation procedures. Life-saving cardiovascular procedures should never be delayed because of coma, which may take days to resolve. Immediate discussion of these issues with an interventional cardiologist is appropriate for all patients who do not have an obvious non-cardiovascular etiology of arrest. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4490?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation of the survivor of sudden cardiac arrest\", section on 'Coronary angiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    TH can be started during catheterization using surface cooling (ice packs), cold IV fluid administration, or intravascular cooling methods. Case series report good outcomes in patients with cardiovascular shock treated with TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724176\">",
"    <span class=\"h1\">",
"     THERAPEUTIC (INDUCED) HYPOTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic injury is the most common cause of death in patients with out-of-hospital cardiac arrest and contributes to the mortality of in-patients with cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/42\">",
"     42",
"    </a>",
"    ]. Lowering brain temperature to 32 to 34",
"    <strong>",
"     &deg;",
"    </strong>",
"    C during the first few hours after cardiac arrest reduces the risk of neurologic injury. According to an observational study of 151 patients, the risk of death increases for each degree over 37&deg;C during the first 48 hours after arrest (OR 2.26; 95% CI 1.24-4.12) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/43\">",
"     43",
"    </a>",
"    ]. In this section, the implementation and evidence for therapeutic hypothermia following cardiac arrest is reviewed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2691802\">",
"    <span class=\"h2\">",
"     Indications and contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients not following commands or showing purposeful movements following resuscitation from cardiac arrest are eligible for TH. Absolute contraindications include active noncompressible bleeding and a do-not-resuscitate order. While the original trials of TH excluded pregnant or hemodynamically unstable patients, good outcomes have been reported in these patients in subsequent observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/40,41,44,45\">",
"     40,41,44,45",
"    </a>",
"    ]. TH can be induced during coronary catheterization and in patients receiving thrombolytics, although the risk of bleeding is increased in these cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724204\">",
"    <span class=\"h2\">",
"     Timing and duration of therapeutic hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal speed for inducing therapeutic hypothermia (TH) and the ideal duration of treatment are unknown. We suggest the goal of achieving TH (defined as a core temperature between 32 to 34",
"    <strong>",
"     &deg;",
"    </strong>",
"    C)",
"    <strong>",
"    </strong>",
"    within 6 hours and maintaining it for 12 to 24 hours.",
"   </p>",
"   <p>",
"    Animal studies and human studies using registry data suggest that TH confers no benefit when started more than six hours after the return of spontaneous circulation (ROSC), while treatment instituted sooner than six hours is associated with improved outcomes. Representative studies include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective observational study of 49 consecutive post-cardiac arrest patients found that a shorter time to reach the goal temperature for TH correlated with improved neurologic outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A retrospective study using registry data found no significant difference in outcome among 975 patients treated with TH when the goal temperature was reached within three to six hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two randomized trials reported no improvement in functional outcomes for subjects cooled in the ambulance compared to those cooled in the emergency department [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cooling a patient for less than 6 to 12 hours after cardiac arrest is unlikely to be effective. Animal studies suggest that one hour of TH is only beneficial when the treatment is in place prior to or within moments of the ROSC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Intra-arrest hypothermia is currently not practical in clinical care.",
"   </p>",
"   <p>",
"    Based upon the evidence available, TH should be maintained for 12 to 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. No randomized trials in humans have directly compared different durations of TH after cardiac arrest, but clinical studies demonstrating the benefit of TH have used this time frame. There are limited data about longer treatment in animal studies. Neonatal hypoxic-ischemic encephalopathy has been treated with 72 hours of hypothermia. Some cases series using hypothermia durations up to 72 hours have been reported for severe post-arrest brain injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724218\">",
"    <span class=\"h2\">",
"     Methods for implementing therapeutic hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should cool patients using intravascular or surface cooling methods that are readily available and familiar. Many patients are already mildly hypothermic (35 to 35.5&deg;C) after the return of spontaneous circulation (ROSC) from the mixing of cooler peripheral blood with core blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,3,52\">",
"     2,3,52",
"    </a>",
"    ]. Therefore, minimally invasive techniques can often achieve target temperatures quickly.",
"   </p>",
"   <p>",
"    Intravenous infusion of 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of cold (4&deg;C [39&deg;F]) isotonic saline, using a pressure bag to increase the rate of administration, reduces the core temperature by &gt;2&deg;C per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/47,53,54\">",
"     47,53,54",
"    </a>",
"    ]. One liter of pressure-infused cold saline infused over approximately 15 minutes can drop the core temperature by approximately 1&deg;C. The rate of temperature reduction using this method is comparable or faster than that achieved with endovascular catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/55\">",
"     55",
"    </a>",
"    ]. Surface cooling methods, including ice packs, cooling blankets, cooling vests, and cold water immersion, can reduce the core body temperature by 0.5 to 1&deg;C per hour.",
"   </p>",
"   <p>",
"    Our local regimen for inducing therapeutic hypothermia is to infuse cold saline using a pressure bag while simultaneously implementing surface cooling using cooling blankets above and below the patient and ice packs applied to the axillae, groin, and neck. Alternatively, cool water baths or cool water and fans can be used, as is done to treat patients with heat exhaustion. Shivering is common and may be too fine to see. Sedation and potentially neuromuscular blockade may be necessary to facilitate cooling. (See",
"    <a class=\"local\" href=\"#H734207\">",
"     'Sedation and suppression of shivering'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no evidence demonstrating the superiority of any cooling method and in clinical practice a combination of intravascular and surface cooling is commonly employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/4,5,32\">",
"     4,5,32",
"    </a>",
"    ]. The lone observational study comparing intravascular and surface cooling methods found that neither the time needed to reach the goal temperature nor neurologic outcome was significantly different in the two groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both surface and intravascular cooling devices are effective at maintaining a goal temperature for 12 to 24 hours. However, the effect of mild temperature fluctuations and excessive hypothermia on patient outcomes is unknown, and thermostatically controlled devices provide the most precise minute-to-minute temperature regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734207\">",
"    <span class=\"h2\">",
"     Sedation and suppression of shivering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shivering raises body temperature and must be suppressed in patients being treated with therapeutic hypothermia (TH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/53,58-60\">",
"     53,58-60",
"    </a>",
"    ]. Failure to suppress shivering is a common reason for delays in achieving goal temperatures when instituting TH. Therefore, we suggest titrating sedation to shivering suppression, rather than using standard sedation scales. High doses of sedatives are frequently necessary to accomplish this.",
"   </p>",
"   <p>",
"    A continuous infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , with or without intermittent treatment with benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ), is one effective approach to sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/61\">",
"     61",
"    </a>",
"    ]. We start with a propofol infusion at 30",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute and titrate as needed to a maximum dose of 50",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. If this is ineffective, we add fentanyl in boluses of 0.1",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    or as a continuous infusion starting at 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour.",
"   </p>",
"   <p>",
"    In hypotensive patients, a continuous infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    (2 to 10",
"    <span class=\"nowrap\">",
"     mg/hour)",
"    </span>",
"    is an effective alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , but accumulation of this drug may interfere with subsequent neurologic evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/62\">",
"     62",
"    </a>",
"    ]. Studies in healthy volunteers have demonstrated a decrease in metabolism and excretion of midazolam during the induction of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/63\">",
"     63",
"    </a>",
"    ]. Consequently, patients receiving infusions of midazolam may require days to clear the drug. No studies have evaluated the effect of midazolam on neurologic prognostication after cardiac arrest.",
"   </p>",
"   <p>",
"    Intermittent treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    can suppress shivering, but the proconvulsant effects of its primary metabolite normeperidine makes this drug unappealing, particularly in post-cardiac arrest patients. Moreover, meperidine is not recommended in patients with renal dysfunction, which is common in the post-cardiac arrest population.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     Dexmedetomidine",
"    </a>",
"    has been proposed for shivering suppression, but its use is limited by the side effects of hypotension and bradycardia.",
"   </p>",
"   <p>",
"    Neuromuscular blockade is highly effective at suppressing shivering, but can mask seizures, which develop in 3 to 44 percent of post-cardiac arrest patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,4,64-67\">",
"     2,4,64-67",
"    </a>",
"    ]. Continuous electroencephalogram monitoring is needed for the safe use of neuromuscular blockade. A significant proportion of post-arrest seizures are refractory to single agent therapy. Treatment with a variety of agents, including valproic acid,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , has been studied and the rates of seizure cessation are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. As there are no trials specifically evaluating the treatment of seizures following cardiac arrest, many clinicians use the same approach as that for status epilepticus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=see_link&amp;anchor=H33#H33\">",
"     \"Status epilepticus in adults\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H734178\">",
"    <span class=\"h2\">",
"     Temperature monitoring and rewarming",
"    </span>",
"    &nbsp;&mdash;&nbsp;Core body temperature should be monitored continuously during therapeutic hypothermia (TH). The gold standard for core temperature measurement is central venous temperature, but several surrogates are available. In order of preference, surrogate monitoring methods include esophageal, bladder, or rectal probes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Esophageal temperature measurement is the most accurate surrogate method used to follow core temperature during the induction of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Bladder temperature may be erroneous if urine output falls below 0.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour. Rectal measurements may lag behind acute changes in core temperature by up to 1.5&deg;C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/71\">",
"     71",
"    </a>",
"    ]. Many rectal temperature probes can also be placed in the esophagus, yielding a more accurate measurement. Axillary and tympanic measurements are inadequate and misleading during TH and should never be used.",
"   </p>",
"   <p>",
"    During rewarming, the temperature should be raised gradually, with the rate of increase not exceeding 0.5&deg;C per hour. We, along with many other clinicians, advocate a rate of 0.2 to 0.25&deg;C per hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/5,60\">",
"     5,60",
"    </a>",
"    ]. Rapid rewarming can cause electrolyte abnormalities (eg, hyperkalemia), cerebral edema, seizures, and other problems. In animal studies of traumatic brain injury, rapid rewarming",
"    <span class=\"nowrap\">",
"     (&gt;0.5&deg;C/hour)",
"    </span>",
"    eliminated the benefits of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rapid rewarming can occur if the patient&rsquo;s temperature is not closely monitored. The original trials of TH used surface cooling and passive rewarming, but automated devices using surface or intravascular methods are now available to control temperatures during the induction, maintenance, and rewarming phases of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Neither the time to goal temperature nor neurologic outcome differ among patients treated using these two methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/56\">",
"     56",
"    </a>",
"    ]. If such devices are not available, manual rewarming can be employed.",
"   </p>",
"   <p>",
"    Manual rewarming is performed most often when cooling blankets",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ice packs have been used to cool the patient. One approach to gradual rewarming when a cooling blanket is in place is to increase the set point for the patient&rsquo;s temperature by 0.5&ordm;C every three hours until a normal temperature is reached. As an example, if the patient&rsquo;s temperature is 33&deg;C, during the first hour the temperature is set for 33.5&deg;C. After three hours of rewarming, the temperature is set for 34&deg;C. In the case of ice packs, a few can be removed each hour and the rate of rewarming can be used to determine when additional ice should be removed if the patient is rewarming appropriately, or added if the patient is rewarming too quickly.",
"   </p>",
"   <p>",
"    The rate of rewarming can also be increased by raising the room temperature, applying a convective heating device, using heating lamps, or warming the inspired air via the ventilator heating circuit on the humidifier. While there are no data to determine the optimal timing for adding each of these rewarming interventions, it is reasonable to add them one at a time to avoid the adverse effects from overly rapid rewarming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724232\">",
"    <span class=\"h2\">",
"     Potential adverse effects of therapeutic hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most significant side effects of TH are impaired coagulation and increased risk of infection. In addition, TH can adversely affect several other physiologic processes.",
"   </p>",
"   <p>",
"    TH induces a mild coagulopathy. With temperatures below 35&ordm;C, clotting enzymes operate more slowly and platelets function less effectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. As a result, some bleeding is seen in up to 20 percent of patients treated with TH, although transfusion is rarely required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/19,80\">",
"     19,80",
"    </a>",
"    ]. Limited data suggest that the incidence of bleeding is not significantly greater among post-cardiac arrest patients treated with TH compared to those who remain normothermic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of significant bleeding alters the balance of risk and benefit for TH. In the event of significant bleeding (eg, significant decrease in hemoglobin, hemodynamic instability, intracranial hemorrhage, noncompressible site), TH should be stopped and the patient rewarmed to a core temperature &gt;35&deg;C.",
"   </p>",
"   <p>",
"    TH impairs leukocyte function. The incidence of significant infections is likely to increase if hypothermia is maintained longer than 24 hours. While an increase in infection rates has been noted in several cohorts treated with 24 hours of TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,19,81\">",
"     2,19,81",
"    </a>",
"    ], these infections have not been associated with increased mortality.",
"   </p>",
"   <p>",
"    Hypothermia slows cardiac conduction and can provoke arrhythmias, including bradycardia and QT interval prolongation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/82\">",
"     82",
"    </a>",
"    ]. A heart rate in the 40&rsquo;s is common at 33&ordm;C, but does not require intervention if the blood pressure is acceptable. If intervention is needed for ventricular fibrillation or pulseless ventricular tachycardia, animal studies report similar or improved first-shock success with defibrillation in specimens with mild hypothermia compared to those with normothermia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Retrospective and prospective observational data suggest that treatment with TH is not associated with an increased need for vasopressor support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperglycemia due to insulin resistance has been noted during TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/82,87\">",
"     82,87",
"    </a>",
"    ]. Large doses of insulin may be needed in severely hyperglycemic patients. (See",
"    <a class=\"local\" href=\"#H7082998\">",
"     'Glycemic control'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypothermia leads to a &ldquo;cold diuresis,&rdquo; which in turn can cause hypovolemia, hypokalemia, hypomagnesaemia, and hypophosphatemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/88\">",
"     88",
"    </a>",
"    ]. In addition, temperature fluctuations during the induction of TH and rewarming cause potassium to move between the extracellular and intracellular compartments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Therefore, careful monitoring of volume status and measurement of basic electrolytes approximately every three to four hours during temperature manipulation is prudent.",
"   </p>",
"   <p>",
"    TH slows the metabolism and excretion of many drugs and thus the duration of effect may be prolonged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H305621864\">",
"    <span class=\"h2\">",
"     Evidence of benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall benefit of therapeutic hypothermia (TH) in patients who are successfully resuscitated following cardiac arrest was summarized in a systematic review of five randomized and quasi-randomized trials including 481 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/94\">",
"     94",
"    </a>",
"    ]. According to pooled data from the three trials reporting such results, patients treated with TH (n=195) had better cerebral performance (RR 1.55; 95% CI 1.22 to 1.96) and were more likely to survive to hospital discharge (RR 1.35; 95% CI 1.10 to 1.65) than those not treated with TH (n=188). Evidence of benefit according to patients&rsquo; presenting cardiac rhythm is described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733778\">",
"    <span class=\"h3\">",
"     Evidence of benefit in ventricular fibrillation and pulseless ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild therapeutic hypothermia (TH), given according to the parameters described above, decreases mortality and improves neurologic outcome in patients with out-of-hospital cardiac arrest who present with ventricular fibrillation or pulseless ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This has been demonstrated in two randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, subjects were randomly assigned to normothermia or treatment with TH for 24 hours using a goal temperature of 32 to 34&deg;C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2\">",
"       2",
"      </a>",
"      ]. At six months, 56 of the 137 patients (41 percent) treated with TH had died compared to 76 of the 138 normothermic patients (55 percent) (RR 0.74; 95% CI, 0.58-0.95). In addition, 75 (55 percent) of the patients treated with TH had a good neurologic outcome compared to 54 (39 percent) of the normothermic patients (RR 1.40; 95% CI 1.08-1.81).",
"     </li>",
"     <li>",
"      In another trial, 77 subjects were randomly assigned to either normothermia or treatment with TH for 12 hours with a goal temperature of 32&deg;C [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/3\">",
"       3",
"      </a>",
"      ]. The rate of good neurologic outcome, defined as discharge to home or an acute rehabilitation facility, was 49 percent in the TH group and 26 percent in the normothermia group. After adjusting for differences in age and time from collapse to the return of spontaneous circulation, the authors reported the odds ratio for a good outcome with TH, compared to normothermia, to be 5.25 (95% CI, 1.47-18.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results similar to those of the randomized trials have been reported in several non-randomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/4,5,95\">",
"     4,5,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733785\">",
"    <span class=\"h3\">",
"     Evidence of benefit in non-shockable rhythms and in-hospital cardiac arrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic hypothermia (TH) is of potential benefit for minimizing brain injury in all post-cardiac arrest patients, regardless of their arrhythmia or the location of their arrest. The 2010 Guidelines for Advanced Cardiac Life Support recommend TH for all unresponsive adult post-cardiac arrest patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonetheless, evidentiary support for TH in the treatment of patients with arrhythmias other than ventricular fibrillation or pulseless ventricular tachycardia is primarily limited to non-randomized studies using historical or concurrent controls (ie, observational studies with an inherent risk of bias), and further research is required to understand the effects of TH in these patients.",
"   </p>",
"   <p>",
"    Reports supporting the use of TH include one multicenter study of subjects with return of spontaneous circulation following cardiac arrest that reported fewer deaths among the 124 patients with non-shockable arrhythmias treated with TH compared to historical controls not treated with TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/96\">",
"     96",
"    </a>",
"    ]. Other studies have reported similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. However, several studies have not found significant improvement in survival or neurologic outcome among those treated with TH whose presenting arrhythmia was not ventricular fibrillation or pulseless ventricular tachycardia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/5,100-104\">",
"     5,100-104",
"    </a>",
"    ]. A systematic review of ten nonrandomized studies reported significantly lower in-hospital mortality among patients treated with TH (risk ratio 0.84; 95% CI 0.78-0.92), but differences in neurologic outcome at hospital discharge did not reach statistical significance (risk ratio 0.95; 95% CI 0.90-1.01) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Core temperature lability is associated with increased mortality after in-hospital cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/106\">",
"     106",
"    </a>",
"    ], and hospitals in many countries use TH as part of the treatment for in-hospital cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. According to observational data, patients with cardiogenic shock requiring intra-aortic balloon pump support also benefit from TH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724247\">",
"    <span class=\"h1\">",
"     GENERAL CRITICAL CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7083080\">",
"    <span class=\"h2\">",
"     Basic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine interventions associated with excellent critical care should be part of the management of post-cardiac arrest patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/107\">",
"     107",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raising the head of the bed to 30 degrees, which",
"      <strong>",
"      </strong>",
"      helps to prevent aspiration and lowers intracranial pressure (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=see_link&amp;anchor=H26#H26\">",
"       \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Position'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stress ulcer prophylaxis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=see_link\">",
"       \"Stress ulcer prophylaxis in the intensive care unit\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Deep venous thrombosis prophylaxis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in medical patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Early physical and occupational therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enteral feeding can resume once TH is completed, because bowel motility is usually suppressed during hypothermia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7082998\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintain serum glucose between 140 and 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.8 and 10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during the period following cardiac arrest, and strive to avoid hypoglycemic episodes. Hyperglycemia is associated with worse outcomes in post-cardiac arrest patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no additional benefit from tight control of the serum glucose (70 to 108",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    3.9 to 6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    compared to more liberal management (108 to 144",
"    <span class=\"nowrap\">",
"     mg/dL;",
"    </span>",
"    6 to 8.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    following cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/110\">",
"     110",
"    </a>",
"    ]. Multiple studies highlight the increased risk of hypoglycemia when lower target ranges are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/110,111\">",
"     110,111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724254\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7082046\">",
"    <span class=\"h2\">",
"     Assessment of brain injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many post-cardiac arrest patients sustain nonsurvivable neurologic injury. Serial neurologic examinations and ancillary diagnostic tests can identify those patients with no chance of a good neurologic recovery. The neurologic assessment of post-cardiac arrest patients, including clinical evaluation and ancillary testing, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=see_link\">",
"     \"Hypoxic-ischemic brain injury: Evaluation and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724296\">",
"    <span class=\"h2\">",
"     Illness severity scores",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illness severity scores integrate information from multiple organ systems to predict patient outcome. They may provide insight into the prognosis of the post-cardiac arrest patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=see_link\">",
"     \"Predictive scoring systems in the intensive care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several scores have been developed specifically for post-cardiac arrest patients and include event-related data that often are not reliably recorded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/112-115\">",
"     112-115",
"    </a>",
"    ]. Moreover, data about the cardiac arrest event may not predict the clinical course after the first day of hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9724303\">",
"    <span class=\"h1\">",
"     SPECIALIZED CENTERS FOR POST-RESUSCITATION CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regionalized centers for post-cardiac arrest patients have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/117\">",
"     117",
"    </a>",
"    ]. Post-cardiac arrest care requires significant resources and coordination among multiple specialities. Sites that care for more than 50 post-cardiac arrest patients per year have better outcomes than facilities with fewer patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/118\">",
"     118",
"    </a>",
"    ]. Other hospital characteristics, such as cardiac catheterization facilities, are associated with more favorable outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/28/35274/abstract/119\">",
"     119",
"    </a>",
"    ]. Since most hospitals see between 10 and 15 post-cardiac arrest patients per year and some do not have continuous access to cardiac catheterization or electroencephalogram monitoring, it seems reasonable to transfer post-cardiac arrest patients to suitable tertiary care centers whenever feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70225037\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of the post-cardiac arrest patient is complex and involves simultaneous performance of both diagnostic and therapeutic interventions, including the following: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Determining and treating the cause of cardiac arrest",
"     </li>",
"     <li>",
"      Minimizing brain injury",
"     </li>",
"     <li>",
"      Managing cardiovascular dysfunction",
"     </li>",
"     <li>",
"      Managing problems that may arise from global ischemia and reperfusion injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A focused history and physical examination are performed and diagnostic studies obtained in order to identify possible causes for the arrest and ongoing or imminent threats to life. Acute myocardial infarction, cardiomyopathy, and primary arrhythmia are the most common causes of sudden cardiac arrest (SCA), but a broad differential diagnosis should be considered. Common etiologies for SCA are described in the attached tables (",
"      <a class=\"graphic graphic_table graphicRef70060 \" href=\"mobipreview.htm?10/45/10972\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef52416 \" href=\"mobipreview.htm?17/18/17708\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The airway is evaluated first. An obstructed airway will rapidly lead to recurrent cardiac arrest. Initial interventions include ensuring a patent and functioning airway and providing appropriate ventilation. Goals for mechanical ventilation include maintaining a PaCO2 no lower than 40 to 45 mmHg and an oxygen saturation &gt;94 percent. The target PaCO2 values are slightly higher in patients treated with therapeutic hypothermia. (See",
"      <a class=\"local\" href=\"#H9724162\">",
"       'Respiratory considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A baseline neurologic examination should be performed to help determine the possible cause, likely clinical course, and need for neurologic interventions. Temporary avoidance or cessation of neuromuscular blockade and sedation is necessary for a valid examination. Asymmetric neurologic findings are not expected following return of spontaneous circulation (ROSC) and suggest a structural intracranial lesion. (See",
"      <a class=\"local\" href=\"#H43368249\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H919559\">",
"       'Physical examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H43368755\">",
"       'Baseline neurologic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic tests, including an electrocardiogram (ECG), imaging studies, and laboratory tests, are generally required to determine the etiology of cardiac arrest, to confirm endotracheal tube positioning and assess for chest trauma from CPR, and to ascertain the involvement of specific organ systems and gauge the severity of injury. Following the ROSC, a 12-lead ECG should be rapidly obtained and evaluated for signs of ST-elevation myocardial infarction (STEMI) (including a new left bundle branch block) that requires emergent reperfusion therapy. Commonly performed testing is described in the text. (See",
"      <a class=\"local\" href=\"#H70225156\">",
"       'Electrocardiogram'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9724141\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H919578\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate blood pressure must be maintained to avoid exacerbating or causing ischemic brain injury. IV fluids, inotropes, and vasopressors may be needed. Antiarrhythmic drugs should be reserved for patients with recurrent or ongoing unstable arrhythmias. (See",
"      <a class=\"local\" href=\"#H43368511\">",
"       'Maintaining end-organ perfusion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H43368518\">",
"       'Preventing arrhythmia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergent coronary catheterization or reperfusion therapy is indicated for patients with ECG findings of STEMI. Regardless of ECG findings, emergent coronary catheterization may be needed for patients with ongoing hemodynamic instability or evidence of focal wall-motion abnormalities on echocardiogram. In general, we suggest that coronary artery catheterization be performed in the post-arrest patient who does not have an obvious non-cardiovascular etiology of arrest, with precise timing determined by the initial ECG, trajectory of cardiac biomarker levels, presence of shock, and competing needs of ongoing resuscitation procedures. Life-saving cardiovascular procedures should never be delayed because of coma. Immediate consultation with an interventional cardiologist is appropriate for all such patients. (See",
"      <a class=\"local\" href=\"#H43368525\">",
"       'Coronary revascularization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic injury is the most common cause of death in patients with out-of-hospital cardiac arrest. Lowering brain temperature to 32 to 34",
"      <strong>",
"       &deg;",
"      </strong>",
"      C during the first few hours after cardiac arrest reduces the risk of neurologic injury. Therefore, in patients with ventricular fibrillation or pulseless ventricular tachycardia as their presenting arrhythmia who experience a ROSC, we recommend treatment with mild therapeutic hypothermia (TH) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). TH may be of benefit in cardiac arrest patients who present with other arrhythmias and experience a ROSC, but the evidence is weaker. We suggest that this patient population also be treated with TH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9724176\">",
"       'Therapeutic (Induced) hypothermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the goal of achieving TH (defined as a core temperature between 32 to 34",
"      <strong>",
"       &deg;",
"      </strong>",
"      C)",
"      <strong>",
"      </strong>",
"      within 6 hours and maintaining it for 12 to 24 hours. Longer treatment increases the risk of infection. TH induces a mild coagulopathy and should be stopped in the event of significant bleeding. Hypothermia leads to a &ldquo;cold diuresis,&rdquo; which in turn can cause hypovolemia, hypokalemia, hypomagnesemia, and hypophosphatemia. Close monitoring of volume status and serum electrolyte concentrations is necessary during TH. The methods for performing and monitoring TH are described in the text.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/1\">",
"      Nichol G, Thomas E, Callaway CW, et al. Regional variation in out-of-hospital cardiac arrest incidence and outcome. JAMA 2008; 300:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/2\">",
"      Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/3\">",
"      Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/4\">",
"      Sunde K, Pytte M, Jacobsen D, et al. Implementation of a standardised treatment protocol for post resuscitation care after out-of-hospital cardiac arrest. Resuscitation 2007; 73:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/5\">",
"      Rittenberger JC, Guyette FX, Tisherman SA, et al. Outcomes of a hospital-wide plan to improve care of comatose survivors of cardiac arrest. Resuscitation 2008; 79:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/6\">",
"      Tagami T, Hirata K, Takeshige T, et al. Implementation of the fifth link of the chain of survival concept for out-of-hospital cardiac arrest. Circulation 2012; 126:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/7\">",
"      Rittenberger JC, Tisherman SA, Holm MB, et al. An early, novel illness severity score to predict outcome after cardiac arrest. Resuscitation 2011; 82:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/8\">",
"      Reynolds JC, Callaway CW, El Khoudary SR, et al. Coronary angiography predicts improved outcome following cardiac arrest: propensity-adjusted analysis. J Intensive Care Med 2009; 24:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/9\">",
"      Dumas F, Cariou A, Manzo-Silberman S, et al. Immediate percutaneous coronary intervention is associated with better survival after out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region Out of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010; 3:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/10\">",
"      Spaulding CM, Joly LM, Rosenberg A, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997; 336:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/11\">",
"      Moore CL, Copel JA. Point-of-care ultrasonography. N Engl J Med 2011; 364:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/12\">",
"      Rose JS, Bair AE, Mandavia D, Kinser DJ. The UHP ultrasound protocol: a novel ultrasound approach to the empiric evaluation of the undifferentiated hypotensive patient. Am J Emerg Med 2001; 19:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/13\">",
"      Jones AE, Tayal VS, Sullivan DM, Kline JA. Randomized, controlled trial of immediate versus delayed goal-directed ultrasound to identify the cause of nontraumatic hypotension in emergency department patients. Crit Care Med 2004; 32:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/14\">",
"      Scalea TM, Rodriguez A, Chiu WC, et al. Focused Assessment with Sonography for Trauma (FAST): results from an international consensus conference. J Trauma 1999; 46:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/15\">",
"      Kirkpatrick AW, Sirois M, Laupland KB, et al. Hand-held thoracic sonography for detecting post-traumatic pneumothoraces: the Extended Focused Assessment with Sonography for Trauma (EFAST). J Trauma 2004; 57:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/16\">",
"      Metter RB, Rittenberger JC, Guyette FX, Callaway CW. Association between a quantitative CT scan measure of brain edema and outcome after cardiac arrest. Resuscitation 2011; 82:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/17\">",
"      Torbey MT, Selim M, Knorr J, et al. Quantitative analysis of the loss of distinction between gray and white matter in comatose patients after cardiac arrest. Stroke 2000; 31:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/18\">",
"      Yanagawa Y, Un-no Y, Sakamoto T, Okada Y. Cerebral density on CT immediately after a successful resuscitation of cardiopulmonary arrest correlates with outcome. Resuscitation 2005; 64:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/19\">",
"      Nielsen N, Hovdenes J, Nilsson F, et al. Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand 2009; 53:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/20\">",
"      Laurent I, Monchi M, Chiche JD, et al. Reversible myocardial dysfunction in survivors of out-of-hospital cardiac arrest. J Am Coll Cardiol 2002; 40:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/21\">",
"      Donnino MW, Miller J, Goyal N, et al. Effective lactate clearance is associated with improved outcome in post-cardiac arrest patients. Resuscitation 2007; 75:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/22\">",
"      K&aring;gstr&ouml;m E, Smith ML, Siesj&ouml; BK. Cerebral circulatory responses to hypercapnia and hypoxia in the recovery period following complete and incomplete cerebral ischemia in the rat. Acta Physiol Scand 1983; 118:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/23\">",
"      Bisschops LL, Hoedemaekers CW, Simons KS, van der Hoeven JG. Preserved metabolic coupling and cerebrovascular reactivity during mild hypothermia after cardiac arrest. Crit Care Med 2010; 38:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/24\">",
"      Buunk G, van der Hoeven JG, Fr&ouml;lich M, Meinders AE. Cerebral vasoconstriction in comatose patients resuscitated from a cardiac arrest? Intensive Care Med 1996; 22:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/25\">",
"      Buunk G, van der Hoeven JG, Meinders AE. Cerebrovascular reactivity in comatose patients resuscitated from a cardiac arrest. Stroke 1997; 28:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/26\">",
"      Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/27\">",
"      Aufderheide TP, Lurie KG. Death by hyperventilation: a common and life-threatening problem during cardiopulmonary resuscitation. Crit Care Med 2004; 32:S345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/28\">",
"      Kilgannon JH, Jones AE, Shapiro NI, et al. Association between arterial hyperoxia following resuscitation from cardiac arrest and in-hospital mortality. JAMA 2010; 303:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/29\">",
"      Janz DR, Hollenbeck RD, Pollock JS, et al. Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest. Crit Care Med 2012; 40:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/30\">",
"      Bellomo R, Bailey M, Eastwood GM, et al. Arterial hyperoxia and in-hospital mortality after resuscitation from cardiac arrest. Crit Care 2011; 15:R90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/31\">",
"      Kuisma M, Boyd J, Voipio V, et al. Comparison of 30 and the 100% inspired oxygen concentrations during early post-resuscitation period: a randomised controlled pilot study. Resuscitation 2006; 69:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/32\">",
"      Gaieski DF, Band RA, Abella BS, et al. Early goal-directed hemodynamic optimization combined with therapeutic hypothermia in comatose survivors of out-of-hospital cardiac arrest. Resuscitation 2009; 80:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/33\">",
"      Sitzwohl C, Kettner SC, Reinprecht A, et al. The arterial to end-tidal carbon dioxide gradient increases with uncorrected but not with temperature-corrected PaCO2 determination during mild to moderate hypothermia. Anesth Analg 1998; 86:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/34\">",
"      Nishizawa H, Kudoh I. Cerebral autoregulation is impaired in patients resuscitated after cardiac arrest. Acta Anaesthesiol Scand 1996; 40:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/35\">",
"      Sundgreen C, Larsen FS, Herzog TM, et al. Autoregulation of cerebral blood flow in patients resuscitated from cardiac arrest. Stroke 2001; 32:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/36\">",
"      Rudolf J, Ghaemi M, Ghaemi M, et al. Cerebral glucose metabolism in acute and persistent vegetative state. J Neurosurg Anesthesiol 1999; 11:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/37\">",
"      Schaafsma A, de Jong BM, Bams JL, et al. Cerebral perfusion and metabolism in resuscitated patients with severe post-hypoxic encephalopathy. J Neurol Sci 2003; 210:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/38\">",
"      Donnino MW, Rittenberger JC, Gaieski D, et al. The development and implementation of cardiac arrest centers. Resuscitation 2011; 82:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/39\">",
"      Ruiz-Bail&eacute;n M, Aguayo de Hoyos E, Ruiz-Navarro S, et al. Reversible myocardial dysfunction after cardiopulmonary resuscitation. Resuscitation 2005; 66:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/40\">",
"      Hovdenes J, Laake JH, Aaberge L, et al. Therapeutic hypothermia after out-of-hospital cardiac arrest: experiences with patients treated with percutaneous coronary intervention and cardiogenic shock. Acta Anaesthesiol Scand 2007; 51:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/41\">",
"      Skulec R, Kovarnik T, Dostalova G, et al. Induction of mild hypothermia in cardiac arrest survivors presenting with cardiogenic shock syndrome. Acta Anaesthesiol Scand 2008; 52:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/42\">",
"      Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care unit following cardiac arrest. Intensive Care Med 2004; 30:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/43\">",
"      Zeiner A, Holzer M, Sterz F, et al. Hyperthermia after cardiac arrest is associated with an unfavorable neurologic outcome. Arch Intern Med 2001; 161:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/44\">",
"      Rittenberger JC, Kelly E, Jang D, et al. Successful outcome utilizing hypothermia after cardiac arrest in pregnancy: a case report. Crit Care Med 2008; 36:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/45\">",
"      Chauhan A, Musunuru H, Donnino M, et al. The use of therapeutic hypothermia after cardiac arrest in a pregnant patient. Ann Emerg Med 2012; 60:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/46\">",
"      Wolff B, Machill K, Schumacher D, et al. Early achievement of mild therapeutic hypothermia and the neurologic outcome after cardiac arrest. Int J Cardiol 2009; 133:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/47\">",
"      Bernard SA, Smith K, Cameron P, et al. Induction of therapeutic hypothermia by paramedics after resuscitation from out-of-hospital ventricular fibrillation cardiac arrest: a randomized controlled trial. Circulation 2010; 122:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/48\">",
"      Castr&eacute;n M, Nordberg P, Svensson L, et al. Intra-arrest transnasal evaporative cooling: a randomized, prehospital, multicenter study (PRINCE: Pre-ROSC IntraNasal Cooling Effectiveness). Circulation 2010; 122:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/49\">",
"      Kuboyama K, Safar P, Radovsky A, et al. Delay in cooling negates the beneficial effect of mild resuscitative cerebral hypothermia after cardiac arrest in dogs: a prospective, randomized study. Crit Care Med 1993; 21:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/50\">",
"      Zhao D, Abella BS, Beiser DG, et al. Intra-arrest cooling with delayed reperfusion yields higher survival than earlier normothermic resuscitation in a mouse model of cardiac arrest. Resuscitation 2008; 77:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/51\">",
"      Nagao K, Kikushima K, Watanabe K, et al. Early induction of hypothermia during cardiac arrest improves neurological outcomes in patients with out-of-hospital cardiac arrest who undergo emergency cardiopulmonary bypass and percutaneous coronary intervention. Circ J 2010; 74:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/52\">",
"      Callaway CW, Tadler SC, Katz LM, et al. Feasibility of external cranial cooling during out-of-hospital cardiac arrest. Resuscitation 2002; 52:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/53\">",
"      Kim F, Olsufka M, Longstreth WT Jr, et al. Pilot randomized clinical trial of prehospital induction of mild hypothermia in out-of-hospital cardiac arrest patients with a rapid infusion of 4 degrees C normal saline. Circulation 2007; 115:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/54\">",
"      Kliegel A, Losert H, Sterz F, et al. Cold simple intravenous infusions preceding special endovascular cooling for faster induction of mild hypothermia after cardiac arrest--a feasibility study. Resuscitation 2005; 64:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/55\">",
"      Al-Senani FM, Graffagnino C, Grotta JC, et al. A prospective, multicenter pilot study to evaluate the feasibility and safety of using the CoolGard System and Icy catheter following cardiac arrest. Resuscitation 2004; 62:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/56\">",
"      T&oslash;mte &Oslash;, Dr&aelig;gni T, Mangschau A, et al. A comparison of intravascular and surface cooling techniques in comatose cardiac arrest survivors. Crit Care Med 2011; 39:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/57\">",
"      Merchant RM, Abella BS, Peberdy MA, et al. Therapeutic hypothermia after cardiac arrest: unintentional overcooling is common using ice packs and conventional cooling blankets. Crit Care Med 2006; 34:S490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/58\">",
"      Moore TM, Callaway CW, Hostler D. Core temperature cooling in healthy volunteers after rapid intravenous infusion of cold and room temperature saline solution. Ann Emerg Med 2008; 51:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/59\">",
"      Hostler D, Northington WE, Callaway CW. High-dose diazepam facilitates core cooling during cold saline infusion in healthy volunteers. Appl Physiol Nutr Metab 2009; 34:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/60\">",
"      Badjatia N, Strongilis E, Gordon E, et al. Metabolic impact of shivering during therapeutic temperature modulation: the Bedside Shivering Assessment Scale. Stroke 2008; 39:3242.",
"     </a>",
"    </li>",
"    <li>",
"     Rittenberger JC, Polderman K. Post-Arrest Management. Emergency Neurological Life Support Course. file://protocols.enlscourse.org (Accessed on April 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/62\">",
"      Chamorro C, Borrallo JM, Romera MA, et al. Anesthesia and analgesia protocol during therapeutic hypothermia after cardiac arrest: a systematic review. Anesth Analg 2010; 110:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/63\">",
"      Hostler D, Zhou J, Tortorici MA, et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos 2010; 38:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/64\">",
"      Abend NS, Topjian A, Ichord R, et al. Electroencephalographic monitoring during hypothermia after pediatric cardiac arrest. Neurology 2009; 72:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/65\">",
"      Rundgren M, Ros&eacute;n I, Friberg H. Amplitude-integrated EEG (aEEG) predicts outcome after cardiac arrest and induced hypothermia. Intensive Care Med 2006; 32:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/66\">",
"      Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology 1988; 38:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/67\">",
"      Nielsen N, Sunde K, Hovdenes J, et al. Adverse events and their relation to mortality in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia. Crit Care Med 2011; 39:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/68\">",
"      Misra UK, Kalita J, Patel R. Sodium valproate vs phenytoin in status epilepticus: a pilot study. Neurology 2006; 67:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/69\">",
"      Agarwal P, Kumar N, Chandra R, et al. Randomized study of intravenous valproate and phenytoin in status epilepticus. Seizure 2007; 16:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/70\">",
"      Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/71\">",
"      Robinson J, Charlton J, Seal R, et al. Oesophageal, rectal, axillary, tympanic and pulmonary artery temperatures during cardiac surgery. Can J Anaesth 1998; 45:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/72\">",
"      Erickson RS, Kirklin SK. Comparison of ear-based, bladder, oral, and axillary methods for core temperature measurement. Crit Care Med 1993; 21:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/73\">",
"      Suehiro E, Singleton RH, Stone JR, Povlishock JT. The immunophilin ligand FK506 attenuates the axonal damage associated with rapid rewarming following posttraumatic hypothermia. Exp Neurol 2001; 172:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/74\">",
"      Suehiro E, Ueda Y, Wei EP, et al. Posttraumatic hypothermia followed by slow rewarming protects the cerebral microcirculation. J Neurotrauma 2003; 20:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/75\">",
"      Heard KJ, Peberdy MA, Sayre MR, et al. A randomized controlled trial comparing the Arctic Sun to standard cooling for induction of hypothermia after cardiac arrest. Resuscitation 2010; 81:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/76\">",
"      Pichon N, Amiel JB, Fran&ccedil;ois B, et al. Efficacy of and tolerance to mild induced hypothermia after out-of-hospital cardiac arrest using an endovascular cooling system. Crit Care 2007; 11:R71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/77\">",
"      Michelson AD, MacGregor H, Barnard MR, et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994; 71:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/78\">",
"      Reed RL 2nd, Bracey AW Jr, Hudson JD, et al. Hypothermia and blood coagulation: dissociation between enzyme activity and clotting factor levels. Circ Shock 1990; 32:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/79\">",
"      Valeri CR, Feingold H, Cassidy G, et al. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987; 205:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/80\">",
"      Jarrah S, Dziodzio J, Lord C, et al. Surface cooling after cardiac arrest: effectiveness, skin safety, and adverse events in routine clinical practice. Neurocrit Care 2011; 14:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/81\">",
"      Perbet S, Mongardon N, Dumas F, et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. Am J Respir Crit Care Med 2011; 184:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/82\">",
"      Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med 2009; 37:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/83\">",
"      Rhee BJ, Zhang Y, Boddicker KA, et al. Effect of hypothermia on transthoracic defibrillation in a swine model. Resuscitation 2005; 65:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/84\">",
"      Boddicker KA, Zhang Y, Zimmerman MB, et al. Hypothermia improves defibrillation success and resuscitation outcomes from ventricular fibrillation. Circulation 2005; 111:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/85\">",
"      Huynh N, Kloke J, Gu C, et al. The effect of hypothermia \"dose\" on vasopressor requirements and outcome after cardiac arrest. Resuscitation 2013; 84:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/86\">",
"      Roberts BW, Kilgannon JH, Chansky ME, et al. Therapeutic hypothermia and vasopressor dependency after cardiac arrest. Resuscitation 2013; 84:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/87\">",
"      Cueni-Villoz N, Devigili A, Delodder F, et al. Increased blood glucose variability during therapeutic hypothermia and outcome after cardiac arrest. Crit Care Med 2011; 39:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/88\">",
"      Polderman KH, Peerdeman SM, Girbes AR. Hypophosphatemia and hypomagnesemia induced by cooling in patients with severe head injury. J Neurosurg 2001; 94:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/89\">",
"      Clifton GL, Miller ER, Choi SC, Levin HS. Fluid thresholds and outcome from severe brain injury. Crit Care Med 2002; 30:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/90\">",
"      Aibiki M, Kawaguchi S, Maekawa N. Reversible hypophosphatemia during moderate hypothermia therapy for brain-injured patients. Crit Care Med 2001; 29:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/91\">",
"      van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010; 49:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/92\">",
"      Tortorici MA, Kochanek PM, Poloyac SM. Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med 2007; 35:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/93\">",
"      Zhou J, Poloyac SM. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol 2011; 7:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/94\">",
"      Arrich J, Holzer M, Havel C, et al. Hypothermia for neuroprotection in adults after cardiopulmonary resuscitation. Cochrane Database Syst Rev 2012; 9:CD004128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/95\">",
"      Holzer M, Bernard SA, Hachimi-Idrissi S, et al. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med 2005; 33:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/96\">",
"      Arrich J, European Resuscitation Council Hypothermia After Cardiac Arrest Registry Study Group. Clinical application of mild therapeutic hypothermia after cardiac arrest. Crit Care Med 2007; 35:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/97\">",
"      Bernard SA, Jones BM, Horne MK. Clinical trial of induced hypothermia in comatose survivors of out-of-hospital cardiac arrest. Ann Emerg Med 1997; 30:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/98\">",
"      Busch M, Soreide E, Lossius HM, et al. Rapid implementation of therapeutic hypothermia in comatose out-of-hospital cardiac arrest survivors. Acta Anaesthesiol Scand 2006; 50:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/99\">",
"      Storm C, Steffen I, Schefold JC, et al. Mild therapeutic hypothermia shortens intensive care unit stay of survivors after out-of-hospital cardiac arrest compared to historical controls. Crit Care 2008; 12:R78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/100\">",
"      Oddo M, Schaller MD, Feihl F, et al. From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest. Crit Care Med 2006; 34:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/101\">",
"      Whitfield AM, Coote S, Ernest D. Induced hypothermia after out-of-hospital cardiac arrest: one hospital's experience. Crit Care Resusc 2009; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/102\">",
"      Don CW, Longstreth WT Jr, Maynard C, et al. Active surface cooling protocol to induce mild therapeutic hypothermia after out-of-hospital cardiac arrest: a retrospective before-and-after comparison in a single hospital. Crit Care Med 2009; 37:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/103\">",
"      Dumas F, Grimaldi D, Zuber B, et al. Is hypothermia after cardiac arrest effective in both shockable and nonshockable patients?: insights from a large registry. Circulation 2011; 123:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/104\">",
"      Storm C, Nee J, Roser M, et al. Mild hypothermia treatment in patients resuscitated from non-shockable cardiac arrest. Emerg Med J 2012; 29:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/105\">",
"      Kim YM, Yim HW, Jeong SH, et al. Does therapeutic hypothermia benefit adult cardiac arrest patients presenting with non-shockable initial rhythms?: A systematic review and meta-analysis of randomized and non-randomized studies. Resuscitation 2012; 83:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/106\">",
"      Suffoletto B, Peberdy MA, van der Hoek T, Callaway C. Body temperature changes are associated with outcomes following in-hospital cardiac arrest and return of spontaneous circulation. Resuscitation 2009; 80:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/107\">",
"      Bjork RJ, Snyder BD, Campion BC, Loewenson RB. Medical complications of cardiopulmonary arrest. Arch Intern Med 1982; 142:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/108\">",
"      Longstreth WT Jr, Diehr P, Cobb LA, et al. Neurologic outcome and blood glucose levels during out-of-hospital cardiopulmonary resuscitation. Neurology 1986; 36:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/109\">",
"      Skrifvars MB, Pettil&auml; V, Rosenberg PH, Castr&eacute;n M. A multiple logistic regression analysis of in-hospital factors related to survival at six months in patients resuscitated from out-of-hospital ventricular fibrillation. Resuscitation 2003; 59:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/110\">",
"      Oksanen T, Skrifvars MB, Varpula T, et al. Strict versus moderate glucose control after resuscitation from ventricular fibrillation. Intensive Care Med 2007; 33:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/111\">",
"      NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/112\">",
"      Adrie C, Cariou A, Mourvillier B, et al. Predicting survival with good neurological recovery at hospital admission after successful resuscitation of out-of-hospital cardiac arrest: the OHCA score. Eur Heart J 2006; 27:2840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/113\">",
"      Haukoos JS, Lewis RJ, Stratton SJ, Niemann JT. Is the ACLS score a valid prediction rule for survival after cardiac arrest? Acad Emerg Med 2003; 10:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/114\">",
"      Oksanen T, Tiainen M, Skrifvars MB, et al. Predictive power of serum NSE and OHCA score regarding 6-month neurologic outcome after out-of-hospital ventricular fibrillation and therapeutic hypothermia. Resuscitation 2009; 80:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/115\">",
"      Rittenberger JC, Martin JR, Kelly LJ, et al. Inter-rater reliability for witnessed collapse and presence of bystander CPR. Resuscitation 2006; 70:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/116\">",
"      Wang HE, Min A, Hostler D, et al. Differential effects of out-of-hospital interventions on short- and long-term survival after cardiopulmonary arrest. Resuscitation 2005; 67:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/117\">",
"      Nichol G, Aufderheide TP, Eigel B, et al. Regional systems of care for out-of-hospital cardiac arrest: A policy statement from the American Heart Association. Circulation 2010; 121:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/118\">",
"      Carr BG, Kahn JM, Merchant RM, et al. Inter-hospital variability in post-cardiac arrest mortality. Resuscitation 2009; 80:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/28/35274/abstract/119\">",
"      Callaway CW, Schmicker R, Kampmeyer M, et al. Receiving hospital characteristics associated with survival after out-of-hospital cardiac arrest. Resuscitation 2010; 81:524.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13838 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-5450C57513-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35274=[""].join("\n");
var outline_f34_28_35274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H70225037\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724120\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7082819\">",
"      MAJOR PROBLEMS AND GOALS OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724127\">",
"      DETERMINING THE CAUSE AND EXTENT OF INJURY AFTER CARDIAC ARREST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368249\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H919559\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368755\">",
"      Baseline neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368801\">",
"      Diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70225156\">",
"      - Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9724141\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H919578\">",
"      - Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724162\">",
"      RESPIRATORY CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368342\">",
"      Initial interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733416\">",
"      Mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3956184\">",
"      Ensuring adequate oxygen delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H733382\">",
"      Interpreting blood gas values during therapeutic hypothermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43368503\">",
"      HEMODYNAMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368511\">",
"      Maintaining end-organ perfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368518\">",
"      Preventing arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43368525\">",
"      Coronary revascularization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724176\">",
"      THERAPEUTIC (INDUCED) HYPOTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2691802\">",
"      Indications and contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9724204\">",
"      Timing and duration of therapeutic hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9724218\">",
"      Methods for implementing therapeutic hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H734207\">",
"      Sedation and suppression of shivering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H734178\">",
"      Temperature monitoring and rewarming",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9724232\">",
"      Potential adverse effects of therapeutic hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H305621864\">",
"      Evidence of benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H733778\">",
"      - Evidence of benefit in ventricular fibrillation and pulseless ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H733785\">",
"      - Evidence of benefit in non-shockable rhythms and in-hospital cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724247\">",
"      GENERAL CRITICAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7083080\">",
"      Basic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7082998\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724254\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7082046\">",
"      Assessment of brain injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9724296\">",
"      Illness severity scores",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9724303\">",
"      SPECIALIZED CENTERS FOR POST-RESUSCITATION CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70225037\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/13838\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/13838|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/45/10972\" title=\"table 1\">",
"      Common etiologies of cardiac arrest in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17708\" title=\"table 2\">",
"      Treatable conditions associated with cardiac arrest",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4490?source=related_link\">",
"      Evaluation of the survivor of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19337?source=related_link\">",
"      Hypoxic-ischemic brain injury: Evaluation and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43047?source=related_link\">",
"      Initial management of the critically ill adult with an unknown overdose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/46/42729?source=related_link\">",
"      Intraoperative fluid management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/25/6554?source=related_link\">",
"      Mechanical ventilation of adults in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33925?source=related_link\">",
"      Oxygenation and mechanisms of hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/56/27527?source=related_link\">",
"      Predictive scoring systems in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11701?source=related_link\">",
"      Serum cardiac enzymes in patients with renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/41/27288?source=related_link\">",
"      Simple and mixed acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18776?source=related_link\">",
"      Stress ulcer prophylaxis in the intensive care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_28_35275="Severity of airflow limitation in COPD";
var content_f34_28_35275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of airflow limitation in COPD (based on postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    )",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        In patients with FEV",
"        <sub>",
"         1",
"        </sub>",
"        /FVC &lt;0.7:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GOLD 1",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        &ge;80 percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GOLD 2",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        50 percent &le;FEV",
"        <sub>",
"         1",
"        </sub>",
"        &lt;80 percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GOLD 3",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        30 percent &le;FEV",
"        <sub>",
"         1",
"        </sub>",
"        &lt;50 percent predicted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GOLD 4",
"       </td>",
"       <td>",
"        Very severe",
"       </td>",
"       <td>",
"        FEV",
"        <sub>",
"         1",
"        </sub>",
"        &lt;30 percent predicted",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second; FVC: forced vital capacity; respiratory failure: arterial partial pressure of oxygen (PaO",
"     <sub>",
"      2",
"     </sub>",
"     ) less than 60 mmHg (8 kPa) with or without arterial partial pressure of CO",
"     <sub>",
"      2",
"     </sub>",
"     (PaCO",
"     <sub>",
"      2",
"     </sub>",
"     ) greater than 50 mmHg (6.7 kPa) while breathing ambient air at sea level.",
"    </div>",
"    <div class=\"reference\">",
"     From: the Global Strategy for Diagnosis, Management and Prevention of COPD 2011, Global Initiative for Chronic Obstructive Lung Disease (GOLD),",
"     <a href=\"file://www.goldcopd.org\" target=\"_blank\">",
"      www.goldcopd.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35275=[""].join("\n");
var outline_f34_28_35275=null;
var title_f34_28_35276="Lower extremity neuropathies";
var content_f34_28_35276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lower extremity peripheral nerve syndromes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"       <td class=\"subtitle1\">",
"        Site of injury",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common peroneal",
"       </td>",
"       <td>",
"        Fibular neck, just below the knee",
"       </td>",
"       <td>",
"        Prolonged lying, leg crossing, squatting, leg cast",
"       </td>",
"       <td>",
"        Foot drop, paresthesias and/or sensory loss over dorsum of foot and lateral shin",
"       </td>",
"       <td>",
"        Weakness on foot dorsiflexion and eversion; sensory loss on dorsum of foot; reflexes normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep peroneal",
"       </td>",
"       <td>",
"        Ankle",
"       </td>",
"       <td>",
"        Tight fitting shoe rim or strap",
"       </td>",
"       <td>",
"        Ankle pain, minimal weakness and sensory loss over web space between digits 1 and 2",
"       </td>",
"       <td>",
"        Minimal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior tibial",
"       </td>",
"       <td>",
"        Tarsal tunnel of ankle",
"       </td>",
"       <td>",
"        Fracture or dislocation of talus, calcaneus, medial malleolus, rheumatoid arthritis, tumor",
"       </td>",
"       <td>",
"        Aching, burning, numbness, tingling on sole of foot, distal foot, toes, and occasionally heel",
"       </td>",
"       <td>",
"        Positive Tinel's sign over nerve posterior to medial malleolus; sensory loss on sole of foot; atrophy of foot muscles if severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Sciatic",
"       </td>",
"       <td>",
"        Sciatic notch/gluteal region",
"       </td>",
"       <td>",
"        Trauma (hip dislocation, fracture, or replacement), prolonged bed rest, deep-seated pelvic mass, piriformis syndrome",
"       </td>",
"       <td>",
"        Leg pain and weakness affecting most lower leg muscles",
"       </td>",
"       <td>",
"        Sensory loss in peroneal, tibial, and sural territories; may spare medial calf and arch of foot; normal knee jerk; absent ankle jerk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mid-thigh",
"       </td>",
"       <td>",
"        Femur fracture, mass, ischemic nerve infarction",
"       </td>",
"       <td>",
"        Similar to above but sparing hamstrings",
"       </td>",
"       <td>",
"        Similar to above",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Femoral",
"       </td>",
"       <td>",
"        Pelvis and anterior thigh",
"       </td>",
"       <td>",
"        Hip or pelvic fracture, hip replacement, lithotomy position, diabetes mellitus",
"       </td>",
"       <td>",
"        Quadriceps weakness and sensory loss",
"       </td>",
"       <td>",
"        Quadriceps weakness; sensory loss over anterior and medial thigh extending down medial shin to arch of foot; reduced or unobtainable knee jerk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lateral femoral cutaneous",
"       </td>",
"       <td>",
"        Inguinal ligament (meralgia paresthetica)",
"       </td>",
"       <td rowspan=\"2\">",
"        Obesity, tight fitting belts, idiopathic",
"       </td>",
"       <td rowspan=\"2\">",
"        Paresthesias and pain radiating down the lateral thigh to knee",
"       </td>",
"       <td rowspan=\"2\">",
"        Sensory loss on lateral thigh",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbosacral radiculopathy",
"       </td>",
"       <td>",
"        See associated table",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35276=[""].join("\n");
var outline_f34_28_35276=null;
var title_f34_28_35277="WHO tumors of the thymus";
var content_f34_28_35277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F53024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F53024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO histologic typing of tumors of the thymus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        1. Epithelial tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        1.1 Thymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.1.1 Type A (spindle cell; medullary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.1.2 Type AB (mixed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.1.3 Type B1 (lymphocyte-rich; lymphocytic; predominantly cortical; organoid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.1.4 Type B2 (cortical)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.1.5 Type B3 (epithelial; atypical; squamoid; well-differentiated thymic carcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        1.2 Thymic carcinoma (type C thymoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.1 Epidermoid keratinizing (squamous cell) carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.2 Epidermoid non-keratinizing carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.3 Lymphoepithelioma-like carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.4 Sarcomatoid carcinoma (carcinosarcoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.5 Clear cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.6 Basaloid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.7 Mucoepidermoid carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.8 Papillary carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1.2.9 Undifferentiated carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        2. Neuroendocrine tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1 Carcinoid tumor (well-differentiated neuroendocrine carcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1.1 classic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1.2 Spindle cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1.3 Pigmented",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1.4 With amyloid (extrathyroid medullary carcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.1.5 Atypical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.2 Small cell carcinoma (poorly differentiated neuroendocrine carcinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.2.1 Mixed small cell-epidermoid keratinizing carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2.3 Large cell neuroendocrine carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        3. Germ cell tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.1 Seminoma (germinoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.2 Embryonal carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.3 Yolk sac tumour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.4 Choriocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.5 Teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.5.1 Mature teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.5.2 Immature teratoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.5.3 With sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3.6 Mixed germ cell tumour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        4. Lymphoid tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.1 Hodgkin's lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.1.1 Nodular sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.2 Large cell lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.2.1 With sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.3 Lymphoblastic lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.4 Anaplastic large cell lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4.5 MALT-type lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        5. Stromal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5.1 Thymolipoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5.2 Thymoliposarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5.3 Solitary fibrous tumour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5.4 Rhabdoid tumour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        6. Tumor-like lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6.1 True thymic hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6.2 Lymphoid hyperplasia (lymphofollicular thymitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6.3 Multilocular thymic cyst",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6.4 Langerhans cell histiocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        7. Neck tumors of thymic or related branchial pouch derivation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7.1 Ectopic hamartomatous thymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7.2 Ectopic cervical thymoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7.3 Spindle epithelial tumour with thymus-like differentiation (SETTLE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7.4 Carcinoma showing thymus-like differentiation (CASTLE)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        8. Metastatic tumours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        9. Unclassified tumours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35277=[""].join("\n");
var outline_f34_28_35277=null;
var title_f34_28_35278="Gram stain stool 1B with answer";
var content_f34_28_35278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Campylobacter jejuni on CAMPY-agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Isolation of Campylobacter jejuni from stool is best accomplished by use of CAMPY-agar, which contains several antibiotics to inhibit normal stool flora. Cultures are incubated at 42&ordm;C in a microaerophilic environment for 48 to 72 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35278=[""].join("\n");
var outline_f34_28_35278=null;
var title_f34_28_35279="Distribution of aerated lung";
var content_f34_28_35279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Distribution of aerated lung follows cephalocaudal and anteroposterior gradients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution (expressed as a percentage) of aerated (open part of bars), poorly aerated (hatched part of bars), and nonaerated (closed part of bars) lung areas along the anteroposterior and the cephalocaudal axis. Each bar represents the lung parenchyma located at a given distance (in centimeters) from the anterior chest wall or from the pulmonary apex. Aerated lung decreases and nonaerated lung increases along the anteroposterior and cephalocaudal axis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Puybasset, L, Cluzel, P, Chao, N, et al., Am J Respir Crit Care Med 1998; 158:1644.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_28_35279=[""].join("\n");
var outline_f34_28_35279=null;
